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p53 is best known as a tumor suppressor that transcriptionally regulates, in 
response to cellular stresses such as DNA damage or oncogene activation, the 
expression of various target genes that mediate cell-cycle arrest, DNA repair, 
senescence or apoptosis—all of these cellular responses are designed to 
prevent damaged cells from proliferating and passing mutations on to the next 
generation. In 50% of human cancers, p53 is defective due usually to somatic 
mutations or deletions primarily in its DNA-binding domain and, to a lesser 
extent, to posttranslational modifications such as phosphorylation, acetylation 
and methylation that affect p53 function and stability. Altered p53 fails to 
regulate growth arrest and cell death upon DNA damage, directly contributing 
to tumor development, malignant progression, poor prognosis and resistance to 
treatment. Conversely, restoring endogenous p53 activity can halt the growth 
of cancerous tumors in vivo by inducing apoptosis, senescence, and innate 
inflammatory responses. cycle arrest, apoptosis, or senescence.
 
 While p53 
plays a protective role in normal somatic tissues by limiting the propagation of 
damaged cells, its powerful growth suppressive and proapoptotic activity 
could be turned into a powerful weapon against cancer cells that have retained 
the functionality of the p53 pathway.  
Searching for small-molecules that activate the transcriptional activity of p53 
would be expected to lead to the discovery of both DNA-damaging agents and 
compounds that are specific for the p53 pathway, including agents that interact 
directly with p53 or that inhibit MDM2 a negative regulator of p53 activity 
and stability. MDM2 is overexpressed in many human tumors and effectively 
impairs the function of the p53 pathway. Therefore, restoration of p53 function 
by antagonizing MDM2 has been proposed as a novel approach for treating 





According to these findings, and as part of a wide medicinal chemistry 
program aimed at identifying small-molecules endowed with antitumor 
activity, different series of  natural compound-inspired derivatives were 
designed as potential p53 modulators. Specifically, my PhD thesis work has 
been centered on two projects: the first was based on the design and synthesis 
of carbazole derivatives as DNA- damaging agents; while the second was 
based on the valuation of natural product analogues designed as both cellular 
cycle modulators and p53-MDM2 interaction inhibitors. The final aim of this 
study was to identify of suitable leads which allow us to deep on the molecular 
complexity of p53 network, improving the antitumor therapeutic arsenal 
The role of natural products as a source for remedies has been recognized 
since ancient times. Despite major scientific and technological progress in 
combinatorial chemistry, drugs derived from natural product still make an 
enormous contribution to drug discovery today. The development of novel 
agents from natural sources presents obstacles that are not usually met when 
one deals with synthetic compounds. For instance, there may be difficulties in 
accessing the source of the samples, obtaining appropriate amounts of the 
sample, identification and isolation of the active compound in the sample, and 
problems in synthesizing the necessary amounts of the compound of interest. 
An analysis of the number of chemotherapeutic agents and their sources 
indicates that over 60% of approved drugs are derived from natural 
compounds.  
During my PhD thesis work three different structural motives present in 
natural products have been considered to be suitable scaffold in the design of 
new antitumoral agents:  carbazoles, acridines and spirooxindole derivatives. 
Carbazoles either in a pure substituted or in an annellated substituted form, 
represent an important and heterogeneous class of anticancer agents, which 
has grown considerably over the last two decades. Recently, Wong et al. have 




by a polycyclic planar system and by a side chain ending with a tertiary amine, 
act stabilized p53 protein by blocking its ubiquitination, without 
phosphorylation of ser15 or ser20 on p53. Furthermore, these derivatives 
induced p53-dependent cell death, activating p53 transcriptional  activity 
Based on the structural cytotoxic requirements for these class of products my  
first PhD project was centered on synthesis of two series of compounds in 
which a carbazole eskeleton were linked by an alkyl chain to an amine (series 
1) or substituted amide (series 2) groups. 
In the other hand, small molecule natural products containing spirooxindole 
derivatives have demonstrated to be invaluable tools in the discovery and 
characterization of critical events for the progression and the regulation of the 
cell cycle. Based on the spirotryprostatin-A structure, during my PhD project 
II I designed, synthesized, and evaluated different series of compounds 
belonging to the diketopiperazine structural class as potential cell cycle 
modulators and cytotoxic agents. Starting from the spirooxindolthiazolidine 
scaffold, amide coupling with Pro derivatives and intramolecular cyclization 
reactions are suitable synthetic methods to generate chemically diverse 
diketopiperazine system, such as hexahydropyrrolo[1,2-a][1,3]thiazolo[3,2-
d]pyrazine-5,10-dione (structure I), hexahydropyrrolo[1,2-a] [1,3]thiazolo[3,4-
d]pyrazine-5,10-dione (structure II) and, spiroindol-2-one[3,30]hexahydro-
5,10H-pyrrolo[1,2-a][1,3]thiazolo[3,4-d]pyrazine-5,10-dione (structure III). 
Some of these compounds, especially those who belong to the series I and II, 
showed interesting cytotoxic activity. 
In the last part of my project, I have designed and synthesized two libraries of 
compounds based on the spirooxindol-thyazolidine moiety, analogues of 
spirooxoindol-pyrrolidine template as p53-MDM2 inhibitors. 
Compounds (3R,7aR)-6-(4-chlorobenzyl)-1H-spiro[imidazo[1,5-c]thiazole-





2‘,5,7(6H,7aH)-trione (43d) are the most potent compounds of this series, 
inhibiting cell growth of different human tumor cells at submicromolar and 
micromolar concentrations, respectively. Compound 42c induces apoptotic 
cell death in human melanoma cell line M14 at 24 h, while in the same 
condition, treatment with 43d shows a clear arrest at G2/M phase inducing 
delay of cell cycle progression. Possibly, these activities may be due to 



































1. PROLIFERATION, CELL CYCLE AND APOPTOSIS IN CANCER 
 
 
1.1 Evolution of cancers 
 
 Since its inception, the study of the molecular basis of cancer has carried 
with it the promise of more refined, more effective cancer therapies. It has 
generally been assumed that because cancers are derived from numerous 
tissues with multiple etiologies, and as tumor progression carries with it a 
bewildering and seemingly endless combination of genetic and epigenetic 
alterations giving rise to a hugely disparate series of diseases, cures for cancer 
must be as diverse as the diseases themselves. 
Although neoplasia involves many other processes that also present 
targets for cancer therapy,
1
 in almost all instances, deregulated cell 
proliferation and suppressed cell death together provide the underlying 
platform for neoplastic progression. The challenge before the research 
community is to identify and understand the molecular anatomy of such 
pivotal steps in tumor progression and to develop therapies that directly these 
points of convergence. 
Cancers are diseases in which unremitting clonal expansion of somatic 
cells kills by invading, subverting and eroding normal tissues. Driving cancer 
development are stochastic somatic cell mutations in genes that govern and 
regulate the diverse aspects of metazoan growth control. Evolution of cancer 
is more complex than the straightforward linear accumulation of oncogenic 
mutations. Potentially oncogenic proliferative signals are coupled to a variety 
of growth-inhibitory processes, such as the induction of apoptosis, 
differentiation or senescence, each of which restricts subsequent clonal 




very rare instances where these growth-inhibitory mechanisms are thwarted 




Figure 1: Evolution of cancer 
 
The processes governing the genesis and progression of cancers are 
evolutionary ones in which natural selection acts upon the inherent or 
acquired diversity of various somatic clones, fostering the outgrowth of those 
with some form of propagative advantage. Metazoans must restrain this 
tendency of individual somatic cells to establish their own autonomous 
colonies, yet at the same time sanction sufficient somatic cell proliferation to 
build and maintain the whole organism. 
Unfortunately, long-lived organisms such as vertebrates need substantial and 




development and long-term maintenance and repair. In teleological terms, the 
evolutionary imperative of vertebrates has been to find a way to allow cell 
proliferation when needed, while at the same time efficiently suppressing the 
genesis of mutated cells leading to deregulated growth. When such measures 
fail, cancer is the inevitable consequence. 
Awareness of the evolutionary nature of cancer offers a number of important 
insights into the malignant process. First, and perhaps most striking, is the 
rarity of the cancer cell. With an estimated mutation rate of some 1 in 22107 
per gene cell division
2
, some 1014 target cells in the average human, and an 
abundant repertoire of genes regulating all aspects of cell expansion, it is 
remarkable that cancers arise in only 1 in 3 lifetimes. This is even more 
striking when one considers that oncogenic mutations, by their nature, foster 
clonal expansion of the affected cell, so propagating the initial mutation and 
thereby increasing the number of target cells available for (and hence the 
probability of) further oncogenic mutation. The rarity of cancer highlights the 
efficacy of potent anti-tumorigenic mechanisms presiding over somatic cells. 
Cancers prevail only when these mechanisms have failed.
3 
Second, cancers ‗progress‘ for the same reason organisms seem to — we see 
only the successes, not the failures. This distorts our statistical view of cancer 
progression. No matter how rare the genesis and evolution of a cancer cell or 
how effective the anti-cancer therapy administered, our perception is only of 
the rare surviving clones that beat all the odds and appear as clinical disease. 
Our inability to discern the mechanisms that thwart the vast majority of 
inchoate tumors deprives us of great insight into how these mechanisms break 
down in cancer and, correspondingly, how we might best reactivate them. 
Third, evolutionary trajectories of cancers are shaped by the selective 
pressures they encounter. Tumors evolve within differing somatic 




Fourth, evolution is an ongoing process. As a neoplasm progresses, expands 
and spreads, it confronts shifting selective pressures. The heterogeneity and 
diversity seen in cancers are vestiges of a dynamic and stochastic 
evolutionary force that varies with differing somatic environments. 
 
1.2 The commonality of cancers 4 
 
Tumors are diverse and heterogeneous, but all share the ability to proliferate 
beyond the constraints limiting growth in normal tissue. Aberrations in the 
regulation of a restricted number of key pathways that control cell 
proliferation and cell survival are mandatory for establishment of all tumors. 
Deregulated cell proliferation together with suppressed apoptosis constitute 
the minimal common platform upon which all neoplastic evolution occurs. 
The critical issue is to identify how tumor cells differ from normal cells and 
how those differences can be exploited therapeutically. 
 
1.2.1. Carcinogenesis 
The transformation of a normal cell into a cancerous cell is a complex and 
multi-step process that include initiation, promotion, and progression (Figure 
2). A number of factors such as diet, toxins, smoking, alcohol, obesity and 
infections are attributed to the development of cancer.  
These factors help in the carcinogenesis process by inducing oxidative 
damage to the DNA. If a cell containing damaged DNA divides before the 
DNA can be repaired, the result is likely to be a permanent genetic alteration 
constituting a first step in carcinogenesis. Body cells that divide rapidly are 
more susceptible to carcinogenesis because there is less opportunity for DNA 
repair before cell division. Factors as the variation in epigenetic code or 
aberrations in tumor suppressor genes, oncogenes, and genes involved in 




suppressor genes or dominant gain of oncogens and/or aneuploidy. Viruses, 
or mutagenic spontaneous changes in the components of signaling pathways 
lead also to cellular transformation and have also been implicated in the cause 




Figure 2. Carcinogenesis is initiated with the transformation of the normal 
cell into a cancer cell (initiated cell).  
 
Causative factors may vary among different cancers but the basic hypothesis 
that a normal human cell has to acquire at least six essential alterations to 
become a malignant cancerous cell in case of solid tumors. These six 
alterations include: the ability to sustain autonomous growth;  the ability to 
avoid growth inhibitory signals;  the evasion of apoptosis;  the potential to 
replicate infinitely;  sustained angiogenesis;  and finally, for the malignant 
tissue to be invasive and metastatic.
1
 
Cancer cells contain many altered and/or mutated genes. These almost always 




control the cell cycle. Their mutated or over-expressed products stimulate 
mitosis even though normal growth signals are absent. Example: many 
tyrosine kinase receptors including epidermal growth factor receptor (EGFR), 
the gene encoding the receptor for epidermal growth factor (EGF) (EGFR is 
also known as HER1). Moreover, for altering cell homeostasis in favor of 
cellular immortality cell has to by bass cell signals, which inhibit 
uncontrolled cell proliferation, they are tumor suppressor genes, and these 
genes normally inhibit mitosis. Example: the p53 gene product normally 
senses DNA damage and either halts the cell cycle until it can be repaired or, 
if the damage is too massive; triggers apoptosis. During the course of cellular 
immortalization different cell signaling pathways are altered in favor of 
tumorogenesis and understanding of these altered cell signaling pathways in 
detail helps to design anticancer therapies 
 
1.3 The cell cycle and its regulation 
 
With advancements in our understanding of the basic mechanisms of 
oncogenesis, we have gained a greater appreciation for the critical role that 
cell cycle regulation plays in malignant transformation and in the development 
of resistance to chemotherapy. Perturbations in the cell cycle are described 
commonly in carcinogenesis. Furthermore, with our improved understanding 
of the effects of chemotherapy on healthy and cancerous cells, it is 
increasingly apparent that the cell cycle also plays a critical role in the 
development of resistance to chemotherapy. These observations have led to 
the development of a new class of anticancer therapeutics in clinical 
development today.
5 
The fundamental task of the cell cycle is to ensure that DNA is faithfully 
replicated once during S phase and that identical chromosomal copies are 
distributed equally to two daughter cells during M phase.
6 




DNA replication and chromosome segregation is insulated from interruption 
by extracellular signals, and its essential and autonomous nature implies that 
damage to the pivotal components would be highly debilitating, if not fatal, to 
cells. Therefore, genes commanding these processes should not be frequent 
targets of mutation, deletion, or amplification in cancer. Oncogenic processes 
exert their greatest effect by targeting particular regulators of GI phase 
progression.
7
 During the G, phase, cells respond to extracellular signals by 
either advancing toward another division or withdrawing from the cycle into a 
resting state (Go).
8
 Unlike transit through the S, G2, and M phases, G 
progression normally relies on stimulation by mitogens and can be blocked by 
antiproliferative cytokines. Cancer cells abandon these controls and tend to 
remain in cycle, and because cell cycle exit can facilitate maturation and 
terminal differentiation, these processes are subverted as well. The decision to 
divide occurs as cells pass a restriction point late in GI, after which they 
become refractory to extracellular growth regulatory signals and instead 
commit to the autonomous program that carries them through to division. An 
appreciation of restriction point control is central to our understanding of how 
and why cancer cells continuously cycle. 
The cell cycle is a critical regulator of the processes of cell proliferation and 
growth as well as of cell division after DNA damage. It governs the transition 
from quiescence (G0) to cell proliferation, and through its checkpoints, 
ensures the fidelity of the genetic transcript. It is the mechanism by which 
cells reproduce, and is typically divided into four phases. The periods 
associated with DNA synthesis (S phase) and mitosis (M phase) are separated 
by gaps of varying length called G1 and G2 (Figure 3). Progression of a cell 
through the cell cycle is promoted by a number of CDKs which, when 
complexed with specific regulatory proteins called cyclins, drive the cell 
forward through the cell cycle. There exist corresponding cell cycle inhibitory 




cycle and stop the cell from proceeding to the next phase of the cell cycle (Fig 
1). The INK4 (for inhibitor of cdk4) class of CDKIs, notably p16lnk4a, 
p15lnk4b, p18lnk4c, and p191nk4 days, bind and inhibit cyclin D–associated 
kinases (CDK2, -4, and -6). The kinase inhibitor protein (KIP) group of CDK 
inhibitors, p21waf1, p27kip1, and p57kip2, negatively regulate cyclin 








Figure 3. The cell cycle. The cell cycle is divided into four phases (G1, S, G2, 
and M). Progression through the cell cycle is promoted by cyclin-dependent 
kinases (CDKs), which are regulated positively by cyclins and negatively by 
CDK inhibitors (CDKIs). The restriction point is the point at which cells 





The pattern of cyclin expression varies with a cell‘s progression through the 
cell cycle, and this specific cyclin expression pattern defines the relative 
position of the cell within the cell cycle.
10
 At least nine structurally related 
CDKs (CDK1- CDK9) have been identified, though not all have clearly 
defined cell cycle regulatory roles. A considerable number of cyclins have 
been identified to date (cyclin A–cyclin T). CDK/cyclin complexes themselves 
become activated by phosphorylation at specific sites on the CDKby 
cdk7/cyclin H, also referred to as CDK-activating kinase (CAK).
11 
Cyclin D 
isoforms (cyclin D1-D3) interact with CDK2, -4, and -6 and drive a cell‘s 
progression through G1. The association of cyclin E with CDK2 is active at 
the G1/S transition and directs entry into S phase. S phase progression is 
directed by the cyclin A/CDK2 complex, and the complex of cyclin A with 
CDK1 (also known as cdc2) is important in G2. CDK1/cyclin B is necessary 
for mitosis to occur. 
 
1.3.1 Cancer as a disease of deregulated cell proliferation 
Each of the pathways that constrains the proliferative response in normal cells 
is perturbed in most cancers. One class of mutations required for tumor 
development acts by short circuiting the normally obligate requirement of 
somatic cells for external mitogenic signals.
12
 Such mutations may involve 
autocrine production of a normally limiting mitogen, activating mutations of 
the mitogen RTKs or G-protein signal transducers such as Ras, or mutations 
affecting one of the many intermediary signal transducing molecules that 
convey mitogenic information to its intracellular targets. A second class of 
growth-deregulating mutations comprises those that target the principal late-
G1 cell-cycle checkpoint regulated by pRB.
13
 Defects in this pathway, which 
may be universal in human cancers, include deletion of the RBgene itself and 




either through direct over-activation of CDKs or through genetic loss of their 
inhibitors.
14
 Another frequent proliferative lesion that has the effect of 
deregulating the cell cycle is  uncontrolled expression of Myc.
15
 Myc 
expression is tightly controlled by mitogen availability in normal cells, but it 
is usually expressed in a deregulated or elevated manner in tumor cells. Myc 
seems to be a strategic controller of cell proliferation that acts pleiotropically 
to coordinate both cell growth 
16




The presence in individual tumors of multiple mutations that affect each of 
the pathways discussed above suggests that each pathway contributes a 
discrete type of proliferative function to the neoplastic phenotype. But 
precisely what such functions are and how and why they interact, remains 
unknown.  
In addition to driving aberrant cell division, mutations in the various 
proliferative control pathways have a profound impact on other cell functions. 
For example, many of the proliferative lesions in tumor cells also contribute 
to the inhibition of differentiation, thereby preventing the elimination of 
progeny cells from the proliferative compartment of many types of tissue. 
pRB, for example, is essential in differentiation of several tissue types 
through interactions with factors such as the helix–loop–helix proteins 
MyoD26
18
 and Id2. Loss or inhibition of pRB function prevents normal 
differentiation, a contribution to tumor development distinct from the direct 
deregulation of cell-cycle progression. Deregulated Myc expression also 




1.4. Apoptosis in health and disease 20 
 
 Apoptosis, or programmed cell death, is a normal component of the 




variety of stimuli and during apoptosis they do so in a controlled, regulated 
fashion. This makes apoptosis distinct from another form of cell death called 
necrosis in which uncontrolled cell death leads to lysis of cells, inflammatory 
responses and, potentially, to serious health problems. Apoptosis, by contrast, 
is a process in which cells play an active role in their own death (which is why 
apoptosis is often referred to as cell suicide). 
Apoptosis occurs during the normal development of multicellular organisms 
and continues throughout adult life. The combination of apoptosis and cell 
proliferation is responsible for shaping tissues and organs in developing 
embryos. For example the apoptosis of cells located in-between the toes 
allows for their separation. Apoptosis is also an important part of the 
regulation of the immune system. T lymphocytes are cells of the immune 
system that are responsible for destroying infected or damaged cells in the 
body. They mature in the thymus, but before they can enter the bloodstream 
they are tested to ensure that they are effective against foreign antigens and are 
also not reactive against normal, healthy cells. Any ineffective or self-reactive 
T-cells are removed through the induction of apoptosis. Problems with the 
regulation of apoptosis have been implicated in a number of diseases. Cancer 
is a disease that is often characterized by too little apoptosis. Cancer cells 
typically possess a number of mutations that have allowed them to ignore 
normal cellular signals regulating their growth and become more proliferative 
than normal. Under normal circumstances damaged cells will undergo 
apoptosis, but in the case of cancer cells mutations may have occurred that 
prevent cells from undergoing apoptosis. In these cases there is no check on 
the cellular proliferation and consequently the disease can progress to the 
formation of tumors. In many cases these tumors can be difficult to kill as 
many cancer treatments rely on damaging the cells with radiation or chemicals 
and mutations in the apoptotic pathway often produce cells that are resistant to 





1.4.1 The apoptotic process 
20
 
 Upon receiving specific signals instructing the cells to undergo apoptosis a 
number of distinctive changes occur in the cell. A family of proteins known as 
caspases are typically activated in the early stages of apoptosis. These proteins 
breakdown or cleave key cellular components that are required for normal 
cellular function including structural proteins in the cytoskeleton and nuclear 
proteins such as DNA repair enzymes. The caspases can also activate other 
degradative enzymes such as DNases, which begin to cleave the DNA in the 
nucleus. 
There are a number of mechanisms through which apoptosis can be induced in 
cells. The sensitivity of cells to any of these stimuli can vary depending on a 
number of factors such as the expression of pro- and anti-apoptotic proteins 
(eg. the Bcl-2 proteins or the Inhibitor of Apoptosis Proteins), the severity of 
the stimulus and the stage of the cell cycle. Some of the major stimuli that can 
induce apoptosis include virus infection, cell stress and DNA damage. 
In some cases the apoptotic stimuli comprise extrinsic signals such as the 
binding of death inducing ligands to cell surface receptors called death 
receptors. These ligands can either be soluble factors or can be expressed on 
the surface of cells such as cytotoxic T lymphocytes. The latter occurs when 
T-cells recognize damaged or virus infected cells and initiate apoptosis in 
order to prevent damaged cells from becoming neoplastic (cancerous) or virus-
infected cells from spreading the infection. Apoptosis can also be induced by 
cytotoxic T-lymphocytes using the enzyme granzyme. In other cases apoptosis 
can be initiated following intrinsic signals that are produced following cellular 
stress. Cellular stress may occur from exposure to radiation or chemicals or to 
viral infection. It might also be a consequence of growth factor deprivation or 
oxidative stress caused by free radicals. In general intrinsic signals initiate 




various bcl-2 proteins can often determine how much cellular stress is 
necessary to induce apoptosis. 
 
 
1.4.2 Cancer as a disease of deregulated survival 
Survival of all somatic cells requires the continuous input of survival and 
trophic signals to suppress apoptosis. The central engines of apoptosis are the 
caspases, cascades of cysteine aspartyl proteases that implement cell death by 
cleaving a variety of intracellular substrates that trigger cell dissolution. 
Caspases are synthesized as latent zymogens that are activated by proteolytic 
cleavage: typically through the action of upstream apical caspases. One such 
pathway is mediated by transmembrane death receptors of the CD95 (Apo-1 
or Fas)/TRAIL/tumor-necrosis factor (TNF) receptor 1 family, whose ligation 
triggers recruitment and assembly of multiprotein complexes that activate  
apical caspase 8.
21
 The other principal death-signaling pathway involves the 
mitochondrion, which acts as an integrating sensor of multiple death insults 
by releasing cytochrome c into the cytosol where it triggers caspase 
activation. The mitochondrial pathway is thought to be the principal target of 
survival signaling pathways, which act by stabilizing mitochondrial  function 
and integrity and suppressing release of cytochrome c.
22
 Once cytochrome c 
has been released from the mitochondrion, it orchestrates assembly of an 
intracellular apoptosome complex that recruits apical caspase 9 via the 
adaptor protein Apaf-1.
23
 The anti-apoptotic oncoproteins Bcl-2 and Bcl-xL, 
which exert their principal effects through stabilization of the mitochondrion, 
are found to be overexpressed in several tumor types and recent analyses have 
indicated that loss of Apaf-1 is a relatively frequent event in malignant 
melanoma that presumably confers resistance to apoptosis.
24
 A particularly 
potent driving force for the suppression of apoptosis in tumor cells is the 




exemplified by the Myc protein. In addition to its well documented growth-
promoting property, Myc was found to be a powerful inducer of apoptosis, 
especially under conditions of stress, genotoxic damage or depleted survival 
factors.
25
 Consideration of such observations led to the proposal that the 
innate apoptotic potential of Myc serves as an inbuilt foil to its oncogenic 














Figure 4 Activation of growth-deregulating lesions triggers ‘sentinel’ functions that 
guard the cell against acquiring mutations or propagating into an inappropriate 
somatic compartment. 
  
In this example, the oncoprotein Myc is shown activating a p53 damage sentinel 
through the ARF/MDM-2 pathway, thereby sensitizing the cell to any DNA damage. 
Myc also promotes release of holocytochrome c from the mitochondrion into the 
cytosol where it triggers apoptosis. Release of holocytochrome c is inhibited by 
paracrine ‗survival‘ signals that are typically restricted both in supply and location. 
Clonal outgrowth driven by relentless Myc expression outstrips survival factor 




Another common pathway through which a wide variety of proliferative 
signals influence the apoptotic program is through induction of ARF, an 
alternate product of the INK4alocus, one of whose functions is to trigger 
upregulation of p53 through its inhibitory action on MDM-2.
26 
Another potent selective pressure in cancers to suppress apoptosis arises from 
the fact that programmed cell death is the typical response of somatic cells to 
many forms of stress and damage; in particular damage to cell DNA (a fact 
exploited by most classical cancer therapeutics). Stress-associated signals that 
activate apoptosis include many of those encountered by the incipient tumor 
cell, including hypoxia and nutrient deprivation, as well as DNA damage 
arising from telomere erosion, defective repair, oncogene deregulation and 
therapy. The p53 protein is important in transducing such diverse signals into 
tumor-suppressive apoptotic or growth-arresting responses, which implies 
that there is strong selection for tumor cells to loose p53 function.
27
 
Importantly, differing p53-activating stresses tend to arise at different stages 
of carcinogenic progression. For example, oncogene deregulation occurs 
early, as it is a prerequisite for clonal expansion, whereas hypoxia is 
significant only after the tumor reaches macroscopic size. Consequently, p53 
exerts a tumor-suppressive role at multiple stages of carcinogenic progression 
(Figure 5), offering an explanation for why loss of p53 has such a profound 

























Figure 5. Many stress signals encountered during tumor progression activate 
p53, resulting in  apoptosis or growth arrest.  
Loss either of the ability to activate p53 or of p53 function itself has 
considerable impact on the ‗success‘ of the carcinogenic process, as it 
increases the chances of a tumor cell surviving progressively adverse 
conditions. Inability to activate p53 in response to stress signals encountered 
early during tumor development, such as deregulated proliferation, may to be 
sufficient to allow the formation of preneoplastic lesions. However, lesions 
that suppress activation of p53 in response to such oncogene-associated stress 
signals do not necessarily block activation of p53 by subsequent events 
encountered during malignant progression, such as DNA damage. 
Consequently, additional alterations in pathways that activate or respond to 
p53, or loss of p53 by direct mutation of the gene itself, may be selected 






1.5 Therapeutic targeting of cell proliferation and apoptosis 
 
Because deregulated proliferation and inhibition of apoptosis lie at the heart 
of all tumor development, they present two obvious targets for therapeutic 
intervention in all cancers. Clearly there are numerous mechanisms through 
which these two defects can occur, and the success of targeted therapy will 
depend to a large part on the molecular fingerprinting of individual tumours.
28
 
Although most existing cancer drugs are anti-mitotic, they act not by 
targeting the specific lesions responsible for deregulated tumor growth, but by 
crudely interfering with the basic machinery of DNA synthesis and cell 
division. Moreover, we now know that the surprising selectivity of such crude 
agents results largely from the increased sensitivity to apoptosis afforded to 
tumor cells by their oncogenic lesions. Drugs designed to specifically inhibit 
growth-deregulating lesions are currently being tested in clinical trials, and 
include inhibitors of RTKs, Ras, downstream signaling kinases such as the 
mitogen-activate protein kinase and Akt pathway, and CDKs. 
At first glance, targeted inhibition of growth-deregulating lesions in cancer 
would be seem to have limited therapeutic efficacy, as they would at best be 
cytostatic. However, unexpected therapeutic bonuses may emerge from such 
an approach because growth deregulation induces a plethora of downstream 
activities in affected cells and their adjacent tissues. Therapeutic inhibition of 
the offending oncoprotein in tumors arising from cell lineages where terminal 
differentiation has been blocked could be sufficient to trigger a resumption of 




The second obvious strategy for cancer therapy is to target the lesions that 
suppress apoptosis in tumor cells. The potent proapoptotic effects of growth-
deregulating mutations mean that tumors are peculiarly dependent upon their 




although apoptosis in tumor cells is sufficiently suppressed to below a critical 
threshold to enable them to survive, they remain acutely sensitized to 
apoptosis. In most, if not all, cancer, this ability to survive results in part from 
inhibition of the p53 pathway, either by inactivating mutations in p53 itself, 
perturbation of the signaling pathways that allow activation of p53 in 
response to stress, or defects in the downstream mediators of p53-induced 
apoptosis. Reintroduction of p53 function is sufficient to induce apoptosis in 
many tumor cells, and several mechanisms to reactivate p53 are being 
considered as therapeutic strategies. These include introduction of wild-type 
p53 into tumors expressing a mutant protein, or inhibition of negative 




Regardless of efficiency in cell killing, the success of repairing the apoptotic 
response in tumor cells depends on the extent to which such therapies confine 
death to the cancer cells, and allow survival of normal tissue. Many 
conventional chemotherapies induce significant toxicity, particularly in 
tissues that normally maintain a proliferative compartment, such as gut 
epithelium and the hematopoietic system. This DNA damage-induced toxicity 
is mediated in part through p53, leading to the suggestion that inhibition of 
p53 in these normal tissues may protect against drug-induced toxicity, thereby 
improving the tolerance of conventional cancer therapies. However, implicit 
in the development of drugs that target specific lesions responsible for tumor 
cell growth is the prediction that these approaches will show significantly 
more specificity for tumor cell killing than conventional therapies. 
Although activation of apoptotic pathways can lead to the death of 
untransformed cells, a process that is essential in normal development, a 
fundamental difference exists between tumor cells and their normal 
counterparts, as normal cells neither have to sustain the pro-apoptotic 




their usual environment in the absence of requisite survival signals. Repair or 
replacement of a single apoptotic signal, be it reactivation of p53 or removal 
of a survival signal, could well prove too much for a tumor cell already 
burdened with a heavy apoptotic load. By contrast, the same perturbation may 
scarcely ruffle the equilibrium of a normal cell, safely buffered in its 
appropriate soma and enjoying the full gamut of trophic support that ensures 








































2. p53: TARGET FOR CANCER THERAPY 
 
 
2.1  p53 network 
 
p53, (53KD) also known as tumor protein 53 (TP53), is a transcription factor 
that regulates the cell cycle and apoptosis, in case of cellular insults, and hence 
functions as a tumor suppressor. p53 has been described as "the guardian of 
the genome", "the guardian angel gene", or the "master watchman", referring 
to its role in conserving stability by preventing genome mutation.  The 
transcription factor p53 responds to diverse cellular stresses to regulate target 
genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or 
changes in metabolism.
31 
In addition, p53 appears to induce apoptosis through 
nontranscriptional cytoplasmic processes.
32
 In unstressed cells, p53 is kept 
inactive essentially through the actions of the ubiquitin ligase MDM2, which 
inhibits p53 transcriptional activity and ubiquitinates p53 to promote its 
degradation.
32
Numerous posttranslational modifications modulate p53 activity, 
most notably phosphorylation and acetylation. Several less abundant p53 
isoforms also modulate p53 activity. Activity of p53 is ubiquitously lost in 
human cancer either by mutation of the p53 gene itself or by loss of cell 
signaling upstream or downstream of p53 
 
2.1.1 Role of p53: normal versus cancer cells 
Activation of p53 can result in a number of cellular responses, and it is 
possible that different responses are induced by different stress signals. There 
is evidence that p53 can play a part in determining which response is induced 
through differential activation of target-gene expression. Although the 
importance of these responses to tumor suppression is clear, previously 




health and disease are being uncovered. The role of p53 in tumor suppression, 
development and ageing is likely to depend on which cellular response is 
activated and on the context in which the activation occurs. p53 is an 
intensively studied protein, its fame stemming mainly from its clear role as a 
tumor suppressor in humans and other mammals.
33 
Loss or mutation of p53 is 
strongly associated with an increased susceptibility to cancer, and most 
functions of p53 have been considered in the light of how p53 might protect 
from malignant progression.
34
 Some p53-null mice can develop normally 
35
 an 
observation that has been taken to rule out major functions for p53 in normal 
physiology. But recent studies are questioning whether p53 is truly such a 
single-minded protein, and other functions of p53 that might be profoundly 
important during normal life are being uncovered. These include roles for p53 
in regulating longevity and ageing, glycolytic pathways that might determine 
endurance and overall fitness, and apoptotic responses during ischaemic and 
other types of stress. Evidence for genetic variations in the activity of the p53 
pathway in humans gives these ideas extra relevance.
36 
One of the major 
mechanisms by which p53 functions is as a transcription factor that both 
positively and negatively regulates the expression of a large and disparate 
group of responsive genes (Figure 6).
37
 Although some of these p53- 
responsive genes have an important role in mediating cell-cycle arrest, 
senescence and apoptosis (the best understood activities of p53), it is now 
evident that the ability of p53 to influence gene expression has wider reaching 
effects. Numerous studies have identified p53-regulated genes that could have 
a role in a number of different and sometimes unexpected responses.
38
 
Although some of these still need to be fully validated, there is now clear 
evidence for a role of p53 in the regulation of glycolysis,
39
 and autophagy, 
40
 
the repair of genotoxic damage, 
41
 cell survival and regulation of oxidative 
stress,
42









 and bone remodeling.
47




is involved, are schematically represented in Figure 6. In these aspects, its 
worthy to analyze there is any cancer cells are expressing wild type p53, and if 
they are expressing, its role in cancer cells has to be studied before clinical use 










Figure 6. Activation and functions of p53. p53 has a key role in integrating 
the cellular responses (pink arrows) to different types of stress (blue arrows).  
 
2.2 The role of p53 in human cancer 
In the two decades since its original discovery, p53 has found a singularly 
prominent place in our understanding of human cancer. Although the 
biochemistry of p53 has been worked out in some detail, our knowledge of the 
biologic consequences of p53 dysfunction is still quite rudimentary. p53 
dysfunction in cancer cells are mainly due to its mutation (50%), epigenetic 
modulation at expressional level and low persistence of p53 protein level due 
to its enhanced turnover. Most p53 mutations found in human cancers are not 
null mutations but rather encode mutant version of the p53 protein that may 
have unwanted activities such as a gain-of-function or be dominant negative 
inhibitors of wt p53 activity. In this regard, it will be important to determine 
how best to harness the complex properties of p53‘s ability to induce cellular 




therapy. Furthermore, a clearer appreciation of the direct interaction epigenetic 
factors with p53 will lead to development of strategies to inhibit tumor 
initiation and progression.  
 
2.2.1 p53; the guardian of the genome 
DNA damage was the first type of stress found to activate p53 and, based on 
this, p53 has been widely regarded as ―the guardian of the genome‖.
48
 
Extensive characterization of the signaling routes that connect DNA damage 
with p53 have identified a cascade of Ser/Thr kinases that includes ATM, 
ATR, Chk1 and Chk2, which phosphorylate p53.
49
 This signaling cascade is 
permanently activated in human cancer, suggesting that the cancerous state is 
intrinsically associated to the generation of DNA damage .
50
 The constitutive 
DNA damage present in cancer cells is thought to emanate primarily from the 
strong generation of reactive oxygen species, 
51
 as well as, from the aberrant 
firing of DNA replication origins.
52
 
.Recent characterization of mice genetically manipulated with a knocked-in 
p53 that cannot be phosphorylated at two of the main residues targeted by 
ATM/ATR/Chk1/Chk2, namely, Ser18 and Ser23 (Ser15 and Ser20 in human 
p53), indicates an important role of these phosphorylation sites in some, but 
not all, the DNA damage induced and p53-dependent responses.
53 
In 
agreement with this, mice carrying p53S18A/S23A alleles are tumor prone,
54 
























Figure 7.  p53 is at the center of a complex web of biological interactions that 
translates stress signals into cell cycle arrest or apoptosis26. 53BP1, p53 
binding protein 1; ATM, ataxia telangiectasia mutated; ATR, ataxia 
telangiectasia and Rad3 related; BAI1, brain-specific angiogenesis inhibitor 
1; BAX, BCL2-associated X protein; BBC3, BCL2 binding component 3 (also 
known as PUMA); DR, death receptor; GADD45, growth arrest and DNA-
damage-inducible 45; KILLER, p53-regulated DNA damage-inducible cell 
death receptor (also known as TNFRSF10B); LRDD, leucine-rich repeats and 
death domain containing; mRNA, microRNA; PMAIP1, phorbol-12-myristate-
13-acetate-induced protein 1 (also known as NOXA); RPRM, reprimo; 
RRM2B, ribonucleotide reductase M2 B; ST13, suppression of tumorigenicity 
13 (also known as p48); TP53I3, tumor protein p53 inducible protein 3; 
THBS1, thrombospondin 1; UV, ultraviolet. 
 
These data suggest that the activation of p53 in response to DNA damage 
occurs through multiple pathways, which in addition to the well-established 
kinase cascade of ATM/ATR/Chk1/Chk2, probably include other kinases such 
as p38, JNK/SAPK and c-Abl (Figure 7).
56




available information gathered from the analysis of epigenetic aberrations 
indicates that the aforementioned DNA damage signaling kinases are not, in 
general, significant targets of genetic and epi-genetic inactivation.
57
 The only 
exception to this is found in hematological malignancies, which present a high 
incidence of mutations in ATM (13–40% depending on the particular type of 
malignancy).
58
 In line with this, a recent large-scale sequencing effort of 210 
diverse human cancers has identified ATM among the three most frequently 
mutated kinases (5% incidence).
59
  Based on the above genetic evidence, it can 
be concluded that DNA damage is conveyed to p53 through multiple 
redundant pathways in which many transducers participate, but none of them 
plays a critical role and, therefore, alteration of a single component does not 
have a significant impact on p53 function. 
According, upstream signaling to p53 increases its level and activates its 
function as a transcription factor in response to a wide variety of stresses, 
whereas downstream components execute the appropriate cellular response 
(see below). The principal sensors seem to be MDM2 and MDM4 and their 
interaction with p53.
60
 In non-stressed conditions these proteins bind p53, 
ubiquitylate it and target it for degradation by the proteasome. In stressed 
conditions the function of the MDM2–MDM4 complex is blocked by 
phosphorylation, protein-binding events and/or enhanced degradation. Hence, 
phosphorylation of MDM4 is essential for the p53 response to ionizing 
radiation, and the response to oncogene activation depends on the binding of 
ARF to MDM2. Many p53-activating small molecules function by causing the 
release of ribosomal proteins from the nucleolus to the nucleoplasm, where 
they bind to MDM2 and MDM4 and inhibit their function. Molecules that 
activate wild-type p53 in tumors by disrupting MDM2 activity can 
compensate for any missing upstream components of the p53 pathway, for 
example the loss of ARF expression that is frequent in cancer cells142. 




their effectiveness. Therefore, the ability to identify tumors in which 
downstream p53 signaling is unaffected is important. The development of 
strategies to ensure that the desired p53 response is initiated when it is 
reactivated might be necessary and could require the judicious use of drug 
combinations. 
 
2.2.1.1. p53; The policeman of the oncogenes 
Among the many and varied stimuli that have been reported to activate p53, 
oncogenic signaling 
61
 has gained much attention because, as DNA damage, is 
also universally present in cancer. Therefore, analogous to the title of 
―guardian of the genome‖, we can also assign to p53 the function of 
―policeman of the oncogenes‖. Oncogenic signaling activates p53 through 
ARF,
62
 which, in turn, interacts with MDM2 inhibiting its p53-ubiquitin ligase 
activity.  
In this manner, ARF-dependent stabilization of p53 results in a dramatic 
increase in p53 activity. Many transcription factors activate ARF in response 
to oncogenic signaling, most notably, Dentin matrix acidic phosphoprotein 
(DMP1).
63 
Mice lacking ARF have a remarkable tumor-prone phenotype, 
64
 
although not as severe as p53-deficient mice,
65
 and there is good genetic 
evidence in mice supporting the relevance of the ARF/MDM2/p53 axis in 
tumor suppression.
66
 Importantly, mice deficient in ARF present a normal 
DNA damage response, indistinguishable from ARF-proficient mice.
67
 
Regarding human cancer, the analysis of (epi)genetic alterations indicate that 
ARF is indeed inactivated with an extraordinary high frequency (~30%).
68
 
However, inactivation of ARF almost invariably occurs in combination with 
the loss of p16INK4a, the cell cycle inhibitor, thus generating an ambiguity 
about which is the key targeted tumor suppressor. In this regard, it should be 
mentioned the existence of germline point mutations that inactivate ARF alone 





Nonetheless, the number of germline mutations that inactivate p16INK4a only 
(i.e., sparing ARF) outnumbers by a factor of ~20 those that inactivate ARF 
alone.
70
 Together, currently available evidence indicates that ARF is an 
important upstream regulator of p53, whose lack of activity has a significant 
impact on cancer.  
 
2.2 p53 co-activators 
 
The interaction between p53 and transcriptional co-activators also influences 
its affinity for promoters. It is therefore plausible that the specific co-factors 
expressed in a particular cellular context determine the repertoire of p53-target 
genes induced, and consequently whether the cell undergoes growth arrest or 




The Myc protein has been implicated as an important determinant of the 
choice between p53-induced growth arrest or apoptosis. Myc inhibits growth 
arrest in response to UV light, g-irradiation and DNA damage inflicted by 
reactive oxygen species.
72
 In the absence of Myc, cells that are exposed to UV 
light arrest in a p53- and Miz-1 (DNA-binding Myc-interacting zinc-finger 1)-
dependent manner through activation of p21. However, when Myc is present, 
exposure to UV triggers its recruitment by Miz-1 to the proximal promoter 
region of p21. This interaction effectively represses p21 induction by p53 and 
other activators.
73
 Intriguingly, this repression appears to be specific for p21, 
because other p53-target genes, such as p53 upregulated modulator of 
apoptosis (PUMA) and PIG3, are induced. This block in p21 induction shifts 
the balance away from growth arrest towards apoptosis.
73b
 It should be noted, 
however, that arrested cells are not necessarily protected from apoptosis. For 
example, normal thymocytes and mature lymphocytes undergo p53-mediated 
apoptosis under certain stress conditions.
74 




other proteins specifically enhances the induction of apoptotic target genes. 
The apoptosis stimulating proteins of p53 (ASPP), for example, increases the 
DNA binding and transactivation activity of p53 on the promoters of apoptotic 
genes (e.g. Bax and PIG3), while failing to promote binding to the p21 
promoter by a mechanism that remains to be defined.
75
 A novel insight into 
the interplay between p53 and its family members, p63 and p73, in the 
induction of apoptosis has been recently revealed by Flores et al.
76
 
Their study of the effect of p63 and p73 on p53 transcriptional activity, using a 
selection of knockout mouse embryo fibroblasts (MEFs), defined two distinct 
classes of target gene. Whereas p53 alone is sufficient for the induction of p21 
and Mdm2, the induction of the apoptotic genes PERP, Bax and Noxa requires 
p53 together with p63 and p73. This finding demonstrates an essential role for 
both p63 and p73 in the efficient induction of apoptotic target genes by p53. 
The mechanism of this cooperation is currently unknown, but it may involve 
an enhanced binding to and/or stabilization of the transcription complex on the 
promoters of p53 apoptotic target genes by the cooperative action of all three 
members.
77
 In addition to the contribution of p63 and p73 to the apoptotic 
function of p53, they play an important role in the precise control of cell death 
during normal mouse development. p73 also plays a role in the induction of 
cell death in response to DNA damage, a process involving cooperation 






2.3 Downstream events of the p53 pathway 
 
Once the p53 protein is activated, it initiates a transcriptional program that 
reflects the nature of the stress signal, the protein modifications and proteins 




sequence, termed the p53- responsive element (RE),
79
 and induces the 
expression of downstream genes. An algorithm that identifies p53-responsive 
genes in the human and mouse genome has been utilized to detect a number of 
new genes regulated by the p53 protein.
80
 The genes in this p53 network 
mainly initiate one of three programs that result in cell cycle arrest, DNA 
repair or apoptosis. 
 
2.3.1 Growth arrest 
p21WAF1/CIP1 is known to be a p53-downstream gene, and has been 
suggested to mediate p53-induced growth arrest triggered by DNA damage. 
The p21 protein is a cyclin-dependent kinase inhibitor that associates with a 
class of CDKs and inhibits their kinase activities. This will facilitate the 
accumulation of hypophosphorylated form of pRB that in turn associates with 
E2F inhibiting its transcriptional activity, leading to cell cycle arrest. As long 
as pRb is bound to E2F, the cell is prevented from entering into S phase. This 
G1 arrest affords the cell time to repair the DNA damage. Should repair be 
unsuccessful, P53 levels drop and CDK-cyclin protein kinase activity resumes, 







2.3.2 DNA repair 
Soon after having established TP53 as the most frequently altered gene in 
human tumors in the 1990s, 
82
  p53 was understood as a major component of 
the DNA damage response pathway.
48,83
 After the introduction of DNA 
injuries the level of p53 protein rises, which in turn induces a transient cell 




translational modifications by specific kinases, such as the strand break sensor 
ataxia telangiectasia mutated protein (Atm), by acetyltransferases like CREB-
binding protein (Cbp)/p300, and by the poly (ADPribose) polymerase 1 (Parp-
1), which prevent proteolysis via the Arf-mouse double minute 2 (Mdm2) 
pathway and/or enhance binding of p53 to consensus sequences within the 
genome.
84
 Initially, investigations on a direct participation of p53 in DNA 
repair were spurred by a number of biochemical observations. Thus, the C-
terminal 30 amino acids of p53 were shown to recognize several DNA 
damage-related structures, such as DNA ends, gaps, and insertion/deletion 
mismatches.
85
 p53 was also demonstrated to catalyze reannealing of short 
stretches of single- and double-stranded DNA and to promote strand exchange 
between them .
86
 Further, p53 binds to three-stranded heteroduplex joints and 
four-stranded Holliday junction DNA structures with localization specifically 
at the junction, suggesting that p53 directly participates in recombinational 
repair.
87
 Moreover, several groups demonstrated a Mg2þ-dependent 3‘–
5‘exonuclease activity intrinsic to p53.
88
 Noticeably, the same central region 
within p53, where tumorigenic mutations are clustered, recognizes DNA 
sequence specifically, is required for junction specific binding of heteroduplex 
joints and is necessary and sufficient for the 3‘–5‘ exonuclease activity on 
DNA.
89
 In addition to p53‘s biochemical activities, numerous reports on 
physical and functional protein interactions further strengthened the proposal 
of a direct role of p53 in nucleotide excision repair (NER), base excision 




Pivotal to the tumor-suppressor activity of p53 is its ability to activate 
apoptosis via multiple different pathways. Since the most-studied function of 
p53 is its role as a transcription factor that can activate transcription of an 




apoptotic genes, as well as its transcriptional repression of anti-apoptotic 
genes, has been widely analyzed..
91
 However, although a large number of 
genes regulated by p53 during induction of apoptosis are known no single 
target gene has been identified whose altered expression alone can sufficiently 
explain p53 mediated transcription dependent apoptosis, and whose genetic 
deficiency phenocopies p53 deficiency in vivo. As an additional mode of 
p53‘s pro-apoptotic activity, recent studies have placed non transcriptional 
pro- apoptotic activities of p53 at the center of an active debate that aims to 
establish a comprehensive understanding of p53- mediated apoptosis.
92 
 
2.3.3.1  Cell cycle arrest or apoptosis? 
The exact criteria that influence p53 to stimulate cell cycle arrest or apoptosis 
are only partially understood and are the subject of intense study. Several 
general factors that influence this decision include p53 expression levels, the 
type of stress signal, the cell type and the cellular context at the time of 
exposure to stress. Several intriguing observations have recently provided 
insight into the apparent intricacies of such cell fate determination. The 
examples described below involve the binding of p53 to its canonical binding 
sequence in target genes. Note, however, that p53 can also activate target 
genes through a non-canonical sequence. The first such example is in the p53-
induced gene 3 (PIG3), which has been implicated in the accumulation of 
reactive oxygen species and apoptosis induction. PIG3 can be induced by p53 
through a microsatellite sequence within its untranslated region.
93
 Another 
recently described example is the gene encoding the pro-apoptotic phosphatase 
PAC1, which is induced through binding of p53 to a novel palindromic 
binding site.
94
 This might represent a new mechanism for transcriptional 
regulation of apoptotic genes by p53, which differs from that already 
described (see below). Exacting discrimination between p53 arrest and 




the latter in tumor suppression. A strong link between the apoptotic function of 
p53 and tumor suppression has been demonstrated using transgenic mice 
bearing an SV40 large T antigen (LT) mutant, which inhibited pRb function 
without directly compromising p53 activity.
95
 p53-mediated growth arrest is 
however impaired in these mice owing to pRb loss of function, but the 
apoptotic activity is functional. These mice develop choroid plexus tumors, 
but at a slow rate owing to continuous p53-dependent apoptosis. Elimination 
of p53 from these mice, by crossbreeding with p53-null mice, resulted in 
aggressive tumor development. This finding suggested that tumor suppression 
is primarily due to p53-mediated apoptosis. The most compelling insight into 
this fundamental question came from a recent study using the Em-myc-
mediated lymphoma mouse model.
96
  The apoptotic pathway of the lymphoma 
cells was blocked either by retroviral expression of bcl-2 or a dominant 
negative caspase-9. The effect of this block on the growth of these lymphomas 
was then tested in recipient mice. In the apoptosis-impaired cells there was no 
selection for p53 mutations, in contrast to cells that had intact apoptotic 
pathways. Remarkably, in the apoptosis-impaired lymphoma cells expressing 
functional p53, the integrity of the genome and the cell cycle checkpoints were 
maintained. Taken together these studies support the notion that apoptosis is 
the critical function of p53 in tumor suppression. 
 
2.3.4 p53 role in transcription dependent apoptosis 
The past twenty-five years have seen intensive and varied investigations to 
better understand the functions that p53 uses to mediate apoptosis. The first 
indication of the role of p53 in apoptosis was obtained using the M1 mouse 
myeloid leukemia cell line lacking endogenous p53. Using M1 cells stably 
transfected with a temperature-sensitive mutant that acquires the conformation 
of wild-type p53 at permissive temperature (32°C), it was observed that upon 




loss of viability with the characteristics of apoptosis.
97
 Several mechanisms 
have been implicated in p53-mediated apoptosis. One is p53 activation to up-
regulation of pro-apoptotic Bax and down-regulation of pro-survival Bcl-
2.
92b,98
 More recently its determined that p53-mediated apoptosis of M1 cells 
involves rapid activation of the pro-apoptotic Fas/CD95 death pathway-via up-
regulation of membrane bound Fas
99
 and the intrinsic mitochondrial pathway, 
which results in activation of caspases 8, 9 and 10. Either Fas blocking 
antibody or inhibition of the apical caspases 8 and 10, were each almost as 
effective as IL-6 in abrogating p53 mediated apoptosis. These observations 
argue that p53 regulation of the bcl-2 members Bax and BcI-2, associated with 
the intrinsic mitochondrial apoptotic pathway, is ancillary to the extrinsic 




































Figure 8. A model for p53-mediated apoptosis. This model depicts the 
involvement of p53 in the extrinsic and intrinsic apoptotic pathways. p53 
target genes are shown in red. The convergence of the two pathways through 
Bid is shown. 
 
 In other cell types up-regulation IGF-BP3,
101
 which sequesters the cell 
survival factor insulin-like growth factor-1 has been associated with p53 
mediated apoptosis.
102
 The gene encoding for the cathepsin-D protease, 
103
 
PAG608 which encodes a nuclear zinc finger protein
104
 and the human 
homolog of the Drosophilasina gene
105
 have also been implicated as mediators 
of p53 induced apoptosis in various cell types. Furthermore, a series of p53-
induced genes (PIG genes) were documented to encode proteins that respond 
to oxidative stress, suggesting that p53-mediated apoptosis involves activation 
of redox- controlling targets followed by increase in ROS, oxidative damage 
to mitochondria and caspase activation.
93, 106
 Along this research line it was 




antioxidant response genes, presumably to prevent the generation of 
antioxidants that could hinder induction of apoptosis.
107
 Clearly established is 
p53‘s role as a nuclear transcription factor with the ability to activate, or 
repress, the expression of many genes. A number of p53 transcriptional 
targets, such as the p53-induced genes BAX, PUMA, NOXA, and the p53-
repressed genes BCL2 and SURVIVIN, represent genes with the potential to 
promote or inhibit apoptosis, respectively, in stressed cells. Puma and Noxa 
are thought to indirectly induce mitochondrial outer membrane 
permeabilization (MOMP), known to be induced by the activation of Bax and 
Bak, via interfering with Bax and Bac interaction with prosurvival Bcl-2 
family members.
108
  Interestingly, it was observed that Puma and Noxa 
differentially contribute to the regulation of p53-mediated apoptotic pathways. 
In normal cells, Puma was found to induce mitochondrial outer membrane 
permeabilization via an ER-dependent pathway; however, upon E1A 
oncoprotein expression, cells also became susceptible to mitochondrial outer 
membrane permeabilization induction by Noxa via an ER-independent 
pathway.
109
 In several instances, transcriptional activation by p53 was 
observed to be dispensable for p53-dependent apoptosis, since mutants p53 
which fail to activate transcription could still induce apoptosis.
110
 In addition, 
p53-dependent apoptosis could occur in the presence of inhibitors of 
transcription and translation.
111
 In recent years it has become clear that p53 
also harbors a direct proapoptotic function at the mitochondria via engaging in 
protein-protein interactions with anti- and pro-apoptotic Bcl2 family members, 










2.3.5 p53 role in mitochondrial mediated apoptosis 
It has been reported, certain transcriptionally inactive mutants of p53 can still 
induce apoptosis when over expressed in tumor cells.
113
 Also, in response to 
some stresses, such as hypoxia, p53 induces apoptosis but does not function as 
a transactivator.
114
 Intriguingly, Moll and al,108 demonstrated that during p53-
dependent apoptosis a fraction cellular p53 protein localizes to mitochondria 
and induces cytochrome c release; however, this is not observed during p p53-
mediated cell cycle arrest.
115
 Additional support for the concept that p53 has a 
cytoplasmic role in apoptosis induction resulted from functional analysis of 
polymorphic variants of p53 (Within exon 4of the p53 gene, a common single-
nucleotide polymorphism (SNP) at codon 72 leads to the incorporation of 
either an arginine (R72) or a proline (P72) at this position of the protein. When 
explored the potential mechanisms underlying the observed functional 
difference between the two p53 variants, made the initially surprising 
discovery that the greater apoptotic potential of the R72 form correlated with 
its much better ability to traffic to mitochondria. Based on these data, therefore 
concluded that the enhanced apoptosis-inducing activity of the R72 protein 
related, at least in part, to its greater mitochondrial localization. An analysis of 
whole cell or mitochondrial extracts by immune precipitation-western blot 
analysis, demonstrated the R72 form of p53 binds better to the mitochondrial 
death-effectors protein BAK than does the P72 variant, correlating with the 
difference in apoptotic potential of the two p53 variants. In healthy cells, Bak 
resides at mitochondria as an inactive monomer. In response to various death 
stimuli, it undergoes an activating allosteric conformational change that 
promotes homo-oligomerization. This leads to formation of a pore in the outer 
mitochondrial membrane, and allows the release of cytochrome c and other 
caspase cascade (Figure 4).
116
 Recently, like BAK, the BCL2 family members 
BAX and BCL-XL have also been implicated in mitochondrial apoptosis 







 Figure 9. The mitochondrial pro-apoptotic activities of p53. In healthy cells (left), 
the proapoptotic BH3-only and effector BH123 proteins (ovals) exists either in 
complex with antiapoptotic proteins Bcl2 family proteins such as BclXL, Bcl2 and 
Mcl-1 (rectangles). Death stimulus induced mitochondrial p53 (triangle) forms a 
complex with BclXL and Bcl2, liberating pro-apoptotic BH3-only proteins 
(derepression by inhibiting their survival function) and BH123 proteins, resulting in 
Bax and Bak homo-oligomerization, activation and mitochondrial membrane 
permeabilization (MMP) to release a host of apoptotic activators. Moreover, 
translocated p53 can bind to Bak by disrupting the inhibitory Bak/Mcl1 complex, 
enabling Bak to ultimately undergo homo-oligomerization and MMP. In addition, in 
cells with a cytosolic BclXL fraction, p53 might activate cytoplasmic Bax through a 
‘hit and run’ mechanism involving an intermediate cytosolic p53/BclXL complex that 
is disrupted by cytosolic Puma, which results in Bax conformational change, 








































3. AIMS OF THE STUDY 
 
p53 is best known as a tumor suppressor that transcriptionally regulates, in 
response to cellular stresses such as DNA damage or oncogene activation, the 
expression of various target genes that mediate cell-cycle arrest, DNA repair, 
senescence or apoptosis—all of these cellular responses are designed to 
prevent damaged cells from proliferating and passing mutations on to the next 
generation. 
82, 118
 In 50% of human cancers, p53 is defective due usually to 
somatic mutations or deletions primarily in its 
DNA-binding domain and, to a lesser extent, to posttranslational modifications 
such as phosphorylation, acetylation and methylation that affect p53 function 
and stability. Altered p53 fails to regulate growth arrest and cell death upon 
DNA damage, directly contributing to tumor development, malignant 
progression, poor prognosis and resistance to treatment.
33b
 Conversely, 
restoring endogenous p53 activity can halt the growth of cancerous tumors in 




p53 protein network in cancer biology has attained much importance because 
of its redundant functions in normal versus cancer cells as well as this 
redundancy influences to different modes of anti-cancer therapy. p53 is the 
most frequently altered protein in human cancer. Approximately 50% of all 
human malignancies harbor mutations or deletions in the TP53 gene that 
disable the tumor suppressor function of the encoded protein.
82,118
 This high 
rate of genetic alterations underscores the important cellular function of p53. 
The tumor suppressor controls a signal transduction pathway evolved to 
protect multicellular organisms from cancer development that could be 
initiated by diverse stresses including DNA damage. p53 is a potent 
transcription factor capable of activating multiple target genes, leading to cell 
cycle arrest, apoptosis, or senescence.
34,85
  While p53 plays a protective role in 




powerful growth suppressive and proapoptotic activity could be turned into a 
powerful weapon against cancer cells that have retained the functionality of 
the p53 pathway.  
Searching for small-molecules that activate the transcriptional activity of p53 
would be expected to lead to the discovery of both DNA-damaging agents and 
compounds that are specific for the p53 pathway, including agents that interact 
directly with p53 
119
 or that inhibit MDM2 a negative regulator of p53 activity 
and stability.
120
 MDM2 is overexpressed in many human tumors and 
effectively impairs the function of the p53 pathway.8 Therefore, restoration of 
p53 function by antagonizing MDM2 has been proposed as a novel approach 




According to these findings, and as part of a wide medicinal chemistry 
program aimed at identifying small-molecules endowed with antitumor 
activity, different series of  compounds were designed as potential p53 
modulators. Specifically, my PhD thesis work has been centered on two 
projects: the first was based on the design and synthesis of acridine derivatives 
as DNA- damaging agents;  while the second was based on the valuation of 
natural product analogues designed as both cellular cycle modulators and p53-
MDM2 interaction inhibitors  
The final aim of this study was to identify of suitable leads which allow us to 



































4. DESIGN AND SYNTHESIS OF A SERIES OF CARBAZOLE-
BASED  DERIVATIVES 
 
 
4.1 Background and design 
 
Natural and synthetic carbazoles, either in a pure substituted or in an 
annellated substituted form, represent an important and heterogeneous class of 
anticancer agents, which has grown considerably over the last two decades.
121 
Many natural carbazoles, such as Murraquinone A and B, and Ellipticine 
(Figure 10) have been tested for cytotoxic activity, some of them have entered 
clinical trials,
122
 but only very few have been approved for the treatment of 
cancer so far, since the clinical application of many carbazoles has 
encountered problems like severe side effects or multidrug resistance. Its 
planar fused ring system can intercalate into the DNA of tumor cells, thereby 
altering the major and minor groove proportions. These alterations to DNA 
structure inhibit both DNA replication and transcription by reducing 
association between the affected DNA and DNA polymerase, RNA 
polymerase and transcription factors. For many carbazoles cytotoxicity can be 
related to DNA-dependent enzyme inhibition such as topoisomerase I/II and 
telomerase. But also other targets such as cyclin-dependent kinases and 








Figure 10. Carbazoles and acridines with antitumor activity 
 
However it has been shown that the presence of a basic side chain improves 
the affinity to the double strand of DNA. One example is the carbazole 
analogue 9-amino-DACA which presents into its structure an acridine core
123
 
linked to protonable amino group. This compound establishes an important 
interaction with phosphate group of guanine G-2. Through recent study has 
been suggested that basic chain established initially an interaction with the 
groove of DNA and then the aromatic core intercalates the double strand. 
124 
An other acridine-based derivative, amsacrin was used combined with 
etoposide as therapy in acute lymphoblastic leukemia.
125




compounds causes relaxation of DNA and consequent alteration of its three-
dimensional properties. This creates a lack of recognition of enzymes involved 
in transcription, duplication and repairing errors. Recently, Wong et al. have 
described a particular activity of a series of acridine derivatives (Figure 11).
126
 
These compounds, characterized by a polycyclic planar system and by a side 
chain ending with a tertiary amine, act stabilized p53 protein by blocking its 




 on p53. Furthermore, 





Figure 11. Acridine derivatives 
 
Based in these findings, we have designed and synthesized two series of 
compounds in which a carbazole skeleton were linked by an alkyl chain to an 
amine (series 1) or substituted amide (series 2) groups. Compounds of series 1 
incorporate an ethyl-, propyl- or butyl- N,N-diethylamino group as substituents 
at position N-9, while the more complex compounds of series 2 contain an 







Figure 12. Compounds synthetized (series 1-2) 
     
4.2 Results and discussion 
 
4.2.1 Chemistry 
For the synthesis of final compounds, N-[(9H-carbazol-9-yl)alkyl)]-N,N-
(diethyl)amine (serie 1) and N-[(9H-carbazol-9-yl)alkyl)]-N,N-(diethyl)amine 
(serie 2) derivatives we using two different strategies. The first series of 
compounds was obtained starting from carbazole 1 through the introduction at 
N-9 position of a brome alkyl side chain. The reaction was carried out in 50% 
toluene solution containing (Br)2alkyl chains of different lengths such as 1,2-
dibromoethane (a), 1,3-dibromopropane (b), and 1,4-dibromobuthane (c) and  






Scheme 1. Synthesis of compounds 1a-c   
 
Then, the corresponding intermediates 1’a-c were treated with diethylamine in 
DMF and CsCO3 to generate the final compounds 1a-1c. 
Our approach to the synthesis of series 2 compounds involves the formation of 
carbazole derivatives via Clauson Kaas reaction
127
 between an appropriate 
enantiopure amino acid such as Gly-OEt, L-Ala-OEt, L-Phe-OEt and 2,5-






Scheme 2.  Synthesis of carbazole derivatives via Clauson Kaas reaction 
 
In this step of reaction the acetic acid promote the opening of 
dimethoxytetrahydrofurane to succinyl aldehyde. Reaction of this dialdehyde 
with the amino group of corresponding amino acids and then Clauson Kaas 





Scheme 3. Clauson Kaas reaction 
 
The attack of other two succinyl aldehyde molecules to pyrrole system, 
through a Fiedel-Craft reaction, leads to the formation first of indole ring  and 











After hydrolysis of ester group in MeOH/H2O using LiOH as base., the 
carboxylic function was funzionalized with two different amine: N,N‘-
dimehyletilendiamine and N-ethylmorpholyne using HOBt, HBTU as 
coupling agents and DIPEA as base (Fig 2, Table 1). 
The use of different length side chain permits evaluation the optimal distance 
between the aromatic core and amino group to interact with the target. 
4.2.2. Biological results 
The target compounds were tested in vitro for tumor cell-growth inhibition on 





















































Table 1. Cytotoxic activity of series 1 and 2  
 
As shown in Table 1, compound 1a-1c (series 1) showed an equipotent 
cytotoxic activity on the MCF-7 cell lines. These data seem indicated a weak 




Unfortunately the introduction of an amino acid side chain reduce  the activity 
of corresponding derivatives. Compounds 2a and 2b containing un glicyl 
residue are more powerful than corresponding alanyl  (3a-b) and phenylalanyl 
(4a-b) derivatives. The presence of a methyl or a benzyl group led to 
significant loss of activity. This data suggest that steric factors might affect the 
activity. In addition, compounds substituted with N,N‘-dimehyletilendiamine 
function (series 1) are more active than N-ethylmorpholyne derivatives (series 
2), demonstrating that the N,N-dimethyl group is an appropriate substituent for 
the interaction with DNA.  
Due to the small structural differences in the more active compounds, a 
rigorous determination of structure–activity relationships is not possible at the 
moment. However, it seems that benzyl side chains was deleterious for any 
activity (compounds 4a, 4b), as well as the introduction of N-ethylmorpholyne 
(2a versus 2b and 3a versus 3b). Our research on these compounds will continue 














Design and synthesis of spirotriprostatin-inspired 


















5. DESIGN AND SYNTHESIS OF 
SPIROTRIPROSTATIN-INSPIRED DIKETOPIPERAZINE SYSTEMS 




5.1 Background and design   
 
The progress in understanding the molecular mechanisms of the mammalian 
cell cycle and its involvement in cancer development has shown that cell cycle 
regulators have a huge prospective both as molecular probes into the process 
as well as potential antitumor agents
2 
. Small molecule natural products have 
demonstrated to be invaluable tools in the discovery and characterization of 
critical events for the progression and the regulation of the cell cycle. 
Therefore, the development of new and specific inhibitors of signal 
transduction cascade pathways will continue to be extremely important in the 
knowledge of the regulatory mechanism of the cell cycle.
130
 
In this context, the isolation of the spirotryprostatins A and B (Fig. 13) from 
the fermentation broth of Aspergillus
131 
 fumigates and the discovery of their 
activity as cell cycle inhibitors has challenged numerous investigators to 











Spirotryprostatins A and B cause G2/M phase cell cycle arrest in tsFT210 cell 
at IC50s of 197.5 and 14.0 M, respectively, according to the therapeutic 
potential of this class of compounds and as part of a wide program centered on 
the development and individuation of new modulators of cell cycle, we have 
focused our attention on the Spirotryprostatin A core as inspiration of 
biologically useful diketopiperazine analogues.
135
 Thus, our initial design 
implicated the modification of the spirocyclic structure replacing the 
pyrrolidine nucleus with a thiazolidine moiety and maintaining unaltered both 
the oxoindole and the indolizidindione fragments (Scheme 5). 
 
 
Scheme 5. Design of spirooxoindolethiazolidine derivatives. 
 
Previous work in our group on the synthesis of quinone-based cytotoxic 
agents, had confirmed that the incorporation of an indolizidindione moiety is 
an effective approach to devise new compounds with potential antitumor 
activity.
136
 In this work,  we  report a full account of our efforts towards the 
synthesis of a new series of diketopiperazine and spirooxoindolethiazolidine 









5.2 Results and discussion  
 
5.2.1 Chemistry  
 
Our approach to the synthesis of the target spiroindol-2- one[3,30]hexahydro-
5,10H-pyrrolo[1,2-a][1,3]thiazolo[3,4-d]pyrazine- 5,10-dione derivatives 
involved the coupling of the spirooxoindolethiazolidine scaffold, obtained 
from isatin derivatives and cysteine, with the N-Boc-Pro residue, followed by 




Scheme 6. Retrosynthetic route to spirooxoindolethiazolidine derivatives. 
 
The application of this synthetic strategy conduced to the oxoindole ring 
opening and to the formation of two new tricyclic systems: the 
hexahydropyrrolo[1,2-a][1,3] thiazolo[3,2-d] pyrazine-5,10- dione (structure I) 
and the hexahydropyrrolo[1,2-a][1,3]thiazol-o[3,4-d]pyrazine-5,10-dione 
(structure II).  
As shown in Scheme 7, the spirooxoindolethiazolidine skeletons (9-12) were 
constructed through microwave assisted condensation between the isatin 
derivatives (4-8), and cysteine ethyl ester in MeOH under argon.
136
 These 
derivatives were obtained with 80–90% yields, as (3R)/(3S) epimeric mixtures 
ranged from 60/40 to 40/60 ratios. Reaction with Boc-Pro, using DIC as 









Scheme 7. Synthesis of 3-ethoxycarbonyl-10a-phenyl(substituted)-
hexahydropyrrolo[1,2-a][1,3] thiazolo[3,2-d]pyrazine-5,10-dione (structure I) 
and the 3-ethoxycarbonyl-3-phenyl(substituted)-hexahydropyrrolo[1,2-





Removal of the N-Boc protecting group of the mixture 13a,b, or 14a,b, or 
15a,b, using TFA in DCM, yielded the 3-ethoxycarbonyl-10a-
phenyl(substituted)-hexahydropyrrolo[1,2-a][1,3]thiazolo[3,2-d]pyrazine-
5,10-dione derivatives (19–21, 23–45% yields) as purecompounds and the 3-
ethoxycarbonyl-3-phenyl(substituted)hexahydropyrrolo[1,2-a][1,3]thiazolo-
[3,4-d] pyrazine-5,10-dione derivatives (26a,b and 28a,b 28–33%) as 
diasteroisomeric mixtures (a/b: 1:3 ratio), while the derivative 27a was 
obtained in 41% yield as pure diasteroisomer (Table 1, entries 1, 2, and 3). 
Under the same conditions, the derivatives 116a,b led to a complex and 
untreatable mixture of reaction (entry 4). 




C NMR resonances and of the stereochemistry in 
final compounds were made by analysis of 2D NMR data, including COSY, 
HSQC, HMBC and NOESY. In the case of the regioisomers 23–27(I), the 
stereochemistry was established on the basis of X-ray diffraction studies of 
compound 25 which indicated 3R,5aS,10aS configurations at the three 
stereogenic centers, as depicted in the ORTEP 
14 









This result showed that the stereomutation at the stereogenic centers C-3 and 
C-5a did not occur during the cyclization process. The stereochemical 





C NMR spectra with those of 25. Unfortunately, we could not 
obtain good crystals for the analysis of any regioisomers 26–28 (II). The 
determination of the configuration at the stereogenic centers was performed by 
an NMR study of representative derivatives 28a and 28b. Considering 
stereogenic centers C-5a and C-10a, we assumed that they maintain their 
configuration 5aS, 10aR after cyclization. NOE enhancement between H-5a 
and H-10a, indicating their cis orientation, is in accordance with this 
hypothesis since the inversion of both centers seems unlikely (Fig. 15). In the 
case of the stereogenic center C-3, a NOE enhancement was observed between 
H-6‘ and H-10a of 28a, while the same enhancement was very weak in 28b. 
Inspections of molecular models obtained by molecular dynamics (MD) 
simulations showed that the distance between H-6‘ and H-10a was about 4.6 Å 
in the 3S, 5aS, 10aR isomer and about 3.5 Å in the 3R, 5aS, 10aR isomer. 
Hence, the 3R configuration was assigned to the 28a isomer The 
stereochemical assignments for compounds 26a, 27a, and 26b were made by 













According to these data, the formation of derivatives I and II implicates an 
unexpected oxoindole ring opening. To the best of our knowledge, no previous 
examples of this reaction performed under the above described conditions 
were reported. Dillman and Cardellina
137
 described the isolation and 
characterization of an unusual sulfur-containing diketopiperazine, from 
extracts of the Bermudian sponge Tedania Ignis, analogue to our 
hexahydropyrrolo[1,2-a][1,3]thiazolo[3,4-d]pyrazine-5,10-dione (structure II). 
On the contrary, neither the isolation nor the synthesis of the 
hexahydropyrrolo[1,2-a][1,3]thiazolo[3,2-d]pyrazine- 5,10-dione (structure I) 
were reported. 
In order to define the factors that could determinate the reaction course we 
performed studies on the influence of solvent, time, and pH in the formation of 
these new derivatives and on their Concerning the solvent, the use of CH3CN 
(entry 5) led to best results and the corresponding I and II structures were 
obtained in an overall yield higher than 85%, while in a less polar aprotic 
solvent as THF (entry 6) the yield was drastically lower (38%). An increase of 
reaction time, up to 24 h, produced a decrease in the I and II yields and a 
reversion to the starting spirooxoindolethiazolidine 5 (entry 7). After 120 h, 
this reversion was nearly complete (entry 8). The use of 1:3 2N HClaq: MeOH 
solution for 24 h, led to deprotected derivatives 20, 21 and 22 (entries 9, 11, 
12). An increase of reaction time (entry 10) determined the formation of 
unidentifiable materials, recovering a 21% of starting isatin 1. It is interesting 
to note that an augment of the proportion of 2N HClaq up to 1:1 in MeOH 
solution favoured, in all cases, the reversion to starting 
spirooxoindolethiazolidine (entry 13).  
As alternative route, the Fmoc derivatives 17 a,b, 18 a,b and 19 a,b (Scheme 
9) were subjected to the treatment with piperidine (25%) in methylene chloride 








Table 2. Results of the acid or base promoted intramolecular cyclization of 3-
prolylspirooxo indolthiazolidine derivatives 
 
 
N Starting R, R1 Solvent Acid/Base T (h)  I (%) IIa (%) IIb (%) Other 
1 13 H CH2Cl2 TFA 2 23 (40) 26a (9) 26b (24)  
2 14 CH3 CH2Cl2 TFA 2 24 (41)  27a (23)   
3 15 Br CH2Cl2 TFA 2 25 (45) 28a (8) 28b (20)  
4 16 H,CH3 CH2Cl2 TFA 2 -  - - 
5 13 H CH3CN TFA 2 23 (50)   26a (10) 26b (25)
 a
  
6 13 H THF TFA 12 23 (20)  26a (5) 26b (12)
a
  
7 13 H CH3CN TFA 24
 
 23 (16) - 26b (22) 9 (20)
a
 
8 13 H CH3CN TFA 120
 





 13 H MeOH HCl
b
 24    20(30)
a
 
10 13 H MeOH HCl
b
 120    5 (21) 
11 14 H MeOH HCl
b
 24    21(37) 
12 15 H MeOH HCl
b
 24    22(31) 
13 13 H MeOH HCl
c
 24    9 (65)
a
 
14 17 H CH2Cl2 Piperidine
d
 1 23(80)    
15 18 CH3 CH2Cl2 Piperidine
d
 1 24 (78)    
16 19 Br CH2Cl2 Piperidine
d
 1 25 (81)    
 
a Similar results were observed from derivatives 10 and 11. b 3:1 MeOH/2 N HCl solution. 
c 1:1 MeOH/2 N HCl solution. d 25% solution 
 
Regarding the stability, the treatment of derivatives 23–25 with 2N 




and the products were recovered unchanged (Scheme 8). The same acid 
treatment on the pure derivatives 26a–28a, 26b, and 28b, led to oxoindole ring 
closing and formation of the corresponding spiro derivatives 23a–25a, 23b, 
and 25b (III), that is, the pentacyclic derivatives designed as analogues of 
spirotryprostatin A, in quantitative yields. This lactamization did not arise 





Scheme 8. Reactivity of I and II derivatives in acid medium. 
 
The acid treatment on the pure derivatives 20a–22a, 20b, and 22b, led to 
oxoindole ring closing and formation of the corresponding spiro derivatives 
23a–25a, 123b, and 25b (III), that is, the pentacyclic derivatives designed as 
analogues of spirotryprostatin A, in quantitative yields. This lactamization did 
not arise when the reaction was carried out in basic media of 
triethylamine/methanol at reflux. After 10 h under basic conditions, we 
observed a partial degradation of all derivatives. 
 According to these findings, we hypothesized that the formation of the 




that involved trans (E) and cis (Z) arrangement of the amide bond of 
deprotected intermediates 20–22. A theoretical conformational analysis of 13a 
(3R), and 13b (3S) in their deprotected and deprotonated state (intermediates 
20a and 20b) was carried out in order to examine possible low-energy 
structures. Amide bond was considered both in the E and Z configurations thus 
obtaining four different isomers (3R–E, 3R–Z, 3S–E, 3S–Z). Starting from 
randomly generated structures, minimization and a 2 ns MD simulations at a 
constant temperature of 500 K were run. The distances between the proline 
amino group and the carboxyl functions at C-2 (oxoindole carbonyl) and at C-
4‘ (ethoxycarbonyl) were monitored along the complete 2 ns MD trajectory. 
From these distances, the two possible orientations assumed by the amide 
bond prompted the system towards two different intramolecular cyclization 
pathways (Fig. 16).  
 
 
Figure 16. Lowest-energy conformers of compound 20b containing a trans 
(left) and cis (right) amide bond. 
 
E isomers are suitable for the C-2 closure (Scheme 9, path I) while Z isomers 
are suitable for the C-4‘ closure (Scheme 11, path II). 
Following the hypothesized reaction mechanisms shown in Scheme 4 (path I), 
the amino group of proline showing an E disposition of the amide bond, 




which evolves to structure I. We calculated the molecular energies of the two 
intermediates with 3R and 3S configuration, and found that the 3S intermediate 
energy was about 8 kcal/mol lower than that observed for 3R. Evoking the 
Evans–Polanyi principle,138 this means that the reaction of the 3S compounds 
through the path I is kinetically favoured compared to the 3R ones. Since 
starting compounds 13–15 quickly interconvert at the C-3 chiral center, 
previous result can explain the stereospecific course of the reaction. 
On the other hand, the Z geometry of the amide bond allows the attack of the 
amino group at C-4‘ carbonyl ester (path II). In the reaction conditions, the 
oxoindole C-2 undergoes a nucleophilic attack from the generated ethoxide 
residue or from other nucleophilic agents present in solution (data not shown). 
Again, the tetrahedrical C-2 intermediate reverts to a more stable carbonyl 
form with ring opening and formation of the regioisomers II. In this case, 
stereogenic center C-3 does not influence the intermediates energy. 
 
 






The C-5 substituent effects are in accordance with reported mechanism. In 
fact, while the yield ratio of the C-5‘ unsubstituted derivatives 23 with respect 
to 26 is 40/33, an electron-donating substituent (CH3) which should reduce the 
C-2 reactivity, decreases the yield ratio of compounds 24 versus 27 to 23/41, 
and an electron-withdrawing substituent (Br) which should enhance the C-2 
reactivity, increases the yield ratio of compounds 25 versus 28 to 45/28. In 
addition, the lack of reactivity observed in the N-methyl derivatives, 16a,b, 
may be attributed to the electrondonating effect of the methyl group which 
prevents the nucleophilic attack at the C-2 carbonyl group. Finally, the higher 
reactivity of the amino group in weak acid solution could be explained if we 
considered that an increase of the acidity (HCl vs TFA) should result in a shift 
toward the unreactive protonated form of the amine group
17 
. 
In basic media, the exclusive and highly efficient formation of structure I 
implies the oxoindole ring opening probably due to nucleophilic attack of 
piperidine at the C-2 carbonyl and successive transamidation by attack of Pro 




Scheme 10. Hypothesized mechanism for the formation of the structure I in 
basic media 
 
This unusual but not unexpected oxoindole ring opening in piperidine media 
could be considered analogous to well described aspartimide ring-opening in 
the peptide chemistry.
139




aspartimide led to ring opening and formation of corresponding a- and b-
piperidides.
140 
The route indicated in Scheme 11, was applied to the synthesis of the 
spiroindol-2-one[3,30]hexahydro-5,10H-pyrrolo[1,2-a][1,3]-thiazolo[3,4-
d]pyrazine-5,10-dione derivatives (structure III). The 
spirooxoindolethiazolidine acid derivatives 9’a,b–12’a,b, synthesized from 
condensation between the corresponding isatin derivatives (5-8) and cysteine 
with 60–70% yields, were chosen as starting material. Coupling with Pro-
OMe, using DIC as coupling agent, under high dilution condition, led to 1/1 
diasteroisomeric mixtures of 23’a,b–26’a,b (70% yields), which were not 
separated in this step. The intramolecular lactamization of these compounds 
using (1/4) 2N HClaq/MeOH solution gave directly the corresponding 
spiroindol-2-one[3,30]hexahydro-5,10H-pyrrolo[1,2-a][1,3]thiazolo[3,4-
d]pyrazine-5,10-dione derivatives (23a,b–26a,b) in ca 90% yields. This 











Scheme 11. Synthesis of spiroindol-2-one[3,30]hexahydro-5,10H-pyrrolo-
[1,2-a][1,3]thiazolo [3,4-d]pyrazine-5,10-dione derivatives (29–32, structure 
III). 
 
NMR analysis of the resulting crude products showed the presence of 
diastereoisomers a/b in 3/2 to 1/1 ratios. The diasteroisomer 29b was isolated 
by precipitation. The diasteroisomeric mixtures 30a,b, and 31a,b were 
chromatographically separated while the mixture 32a,b could not be separated. 
The physicochemical properties and purity of the final compounds were 
assessed by TLC, LC–MS, analytical RP-HPLC, and NMR analysis. The 
determination of the relative configuration at the stereogenic centers was 
performed by a 2D NMR study of isolate 30a, 30b, 31a and 31b derivatives. 
The main difference observed in the 2D NOESY spectra of derivatives ―a‖ 
compared to ―b‖ was the presence in the first of a NOE enhancement between 




C-5‘a and C-10‘a. Inspections of molecular models obtained by MD 
simulations showed that the distance between H-4 and H-10‘a was about 2.9 Å 
in the 3R,50aS,10‘aR isomer and about 4.9 Å in the 3S, 50aS,10aR isomer. 
Hence, the 3R configuration was assigned to the ‗a‘ isomers. 
 
 
Figure 17. Significant NOEs for derivatives a and b. 
 
 
5.2.2 Biological results 
All compounds were evaluated as cytotoxic agents in the Biochemistry and 
Biophysics Department of the Second University of Naples.  
The cytotoxic activity of  hexahydropyrrolo [1,2-a][1,3]thiazolo[3,2-
d]pyrazine-5,10-dione (series I), hexahydropyrrolo [1,2-a][1,3]thiazolo [3,4-
d]pyrazine-5,10-dione (series II) and spiroindol-2-one[3,3‘]hexahydro-5,10H-
pyrrolo[1,2-a] [1,3]thiazolo[3,4-d]pyrazine-5,10-dione (series III) derivatives 
was  evaluated against (MCF-7, T47D, and A-431) cell lines.  
Interestingly, tricyclic derivatives 23, 26a, 27a and 28a resulted active against 
MCF-7 cell growth with IC50 values of 9.1, 14.8, 1.6, and 2.2 M, 
respectively. Compound 24 inhibited A431 cell growth at concentration 28.2 
M. None of compounds belonging to series III showed significant 
cytotoxicity at concentrations below 10
-4
 M towards the cell lines. 
Unfortunately, none of the cytotoxic derivatives showed ability to inhibit the 


































6. DESIGN OF POTENTIAL p53 MODULATORS 
 
 
6.1. Background and design 
 
The ability of p53 to respond to stress signals by triggering cell-cycle arrest 
and cell death by apoptosis is crucial to inhibit tumor development and for the 
response to anticancer therapy.
34-118,143
 Inactivation of p53 by mutation occurs 
in about half of all human tumors
5 
. Tumors that retain wild-type p53 often 
acquire an alternative mechanism for its inactivation, largely through 
deregulation ofMDM2 (murin doubleminute-2) protein. Negative regulation of 
p53 activity and stability is enhanced in many human tumors and effectively 
impairs the activities of the p53 pathway.
145-148
 Therefore, recovery of p53 
activity in cancer cells by antagonizing MDM2 has been proposed as a novel 
approach for treating cancer and validated in vitro by macromolecular 
studies.
149-151 
More recently, genetic and biochemical analysis of the p53-MDM2 interaction 
revealed structural features suggesting that it might be targetable by small 
molecules.
152
 The interaction of MDM2 and p53 was shown to be mediated by 
a deep well-defined hydrophobic cavity on the surface of MDM2.
153
 This cleft 
is filled only by three side chains of the helical region of p53, making this site 
an attractive target to design a small molecule able to mimic the contacts and 
the orientations of these key amino acids, thereby disrupting p53-MDM2 
interaction.
154





  and benzodiazepinediones
157 
 







Figure 18. Small-molecule inhibitors of p53-MDM2 interaction 
 
The first potent and selective small molecule identified as an antagonist of the 
p53-MDM2 interaction, both in vitro and in vivo, were the cis-imidazolidines 
nutlins. These molecules inhibit xenograft tumor growth with no reported side 
effects in normal murine tissues.
158
 More recently, Wang et al. used structure-
based design to develop a new class of small molecule p53-MDM2 antagonists 
based on a spirooxindole core.
159 
 All these inhibitors share a common design 
of a rigid heterocyclic scaffold that can be functionalized with the appropriate 
side chains. A different type of inhibitor of the p53-MDM2 interactions, 
termed RITA, activates p53 by a nongenotoxic mechanism involving the 
disruption of this interaction. However, RITA
160
 binds to p53 and not to 
MDM2. The mechanism by which it interferes with p53-MDM2 binding and 
its effects on the functionality of p53 are not fully understood yet. On the basis 
of these findings and on identification of new activators of p53 pathway in 
tumor cells, we have designed and synthesized two focused libraries of 




analogue of spirooxindole pyrrolidine template.
161
 In this context, the 3‘,4‘ 
hydantoin derived tetracyclic nucleus has turned out to be a very easily 
derivatizable scaffold. In particular, N-6 and N-10 positions were substituted 
with aryl and alkyl groups (Scheme 12). 
 
Scheme 12. Design of new derivatives from spiro(oxindole-3,3’-thiazolidine). 
R= H, CH3, Br; R’ = benzyl derivatives or alkyl; R” = H or acyl derivatives. 
 
In our design strategy, oxoindole, aryl, and alkyl groups are supposed to 







respectively, while the imidazo-[1,5-c]thiazol nucleus would define the 
orientation among them. For the construction of the first library, we selected 
derivatives containing weak releasing (CH3) and acceptor (Br) electron groups 
on the oxoindole moiety and benzyl substituted or 4,4-dimethylcyclohexyl 
side chain on the imidazothiazoledione scaffold. 
On the basis of the ―three finger pharmacophore model‖ described by 
Domling
162 
 and according to the preliminary results of cytotoxic activities, we 
further developed, from the most interesting compounds, a series of 
derivatives containing a third hydrophobic group. In this case, benzoyl, 4-
methylbenzoyl, 4-chlorobenzoyl, and propyonyl groups were introduced into 




The aims of this thesis part were to screen a range of appropriately 
functionalized spiro[imidazo[1,5-c]thiazole-3,3‘-indoline]-2‘,5,7(6H,7aH)-
trione derivatives for cytotoxicity against different cancer cell lines and to 
explore some of the basic biochemical events correlated to their activity using 
a range of cell based approaches. 
The present thesis read more with the synthesis of this new series of 
derivatives and with the understanding of their cytotoxic activity, the 
mechanism of cell cycle perturbation, the p53 expression, and the inhibition of 
p53-MDM2 interaction. 
 
6.2 Results and discussion 
 
6.2.1 Chemistry  
The designed 5‘,6-disubstituted spiro[imidazo-[1,5-c]-thiazole-3,3‘-indoline]-
2‘,5,7(6H,7aH)-trione derivatives (37a-e/40a-e, Table 1) were prepared 



















 Synthesis of spiro[imidazo[1,5-c]-thiazole-3,3‘-indoline]-




a Reagents and conditions: (i) Cys-OEt, NaHCO3 in MeOH, microwave; (ii) triphosgene, 
TEA, THF, room temp, 10 min, then R2-NH2; (iii) MeOH, TEA, reflux, 1-3 h. 
 
The starting spiro-(oxoindolethiazolidine) ethyl ester derivatives (8-12) were 
obtained with 80-90% yields through microwave assisted condensation 
between the corresponding isatin derivatives (4-8) and cysteine ethyl ester as 
we described previously. 
The reaction with triphosgene in tetrahydrofuran and triethylamine followed 
by the in situ addition of amines (a-e) led to the corresponding N-carbamoyl 
derivatives, 42’-45’, as a single isomer as observed by NMR spectrum. 
The synthesis of 3‘-N-carbamoyl intermediates starting from 
spiro(oxoindolethiazolidine) ethyl ester derivatives 9-11 (R1 = H) was 




1-N-carbamoyl derivatives while the reaction performed in THF
a
 led to the 
formation of the desired 3‘-N intermediate. 
The intramolecular cyclization of these derivatives was performed in methanol 
in the presence of TEA at reflux temperature, and the corresponding 
spiro[imidazo[1,5-c]-thiazole-3,3‘-indoline]-2‘,5,7(6H,7aH)-trione derivatives 
(42a-d/45a-d) were obtained with 39-56% overall yields as simple isomer. 
This cyclization was stereospecific toward the 3R,7aR isomer, as the 
corresponding C-3 epimer was not detected in the reaction mixture.
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 The 
assignment of the relative configuration at the C-3 asymmetric center as 3R 
was determined on the basis of a NOE enhancement between H-40 and H-7a 
observed in the 2D NOESY spectra of all compounds. Absolute configurations 
were defined hypothesizing configuration retention at C-7a. 
Finally, the 1‘-acylspiro[imidazo[1,5-c]thiazole-3,3‘-indoline]-2‘,5,7 
(6H,7aH)-trione derivatives (46f-i/47f-i) were prepared in 85-89% yields by 
treatment of starting derivatives 9c and 10d with the corresponding acyl 
chloride (f-i) as depicted in Scheme 14. 
 
Scheme 14. Synthesis of 1‘-acylspiro[imidazo[1,5-c]-thiazole-3,3‘-indoline]-






6.4 Biology and Pharmacology 
 
The spiroimidazothiazoloxoindole derivatives were examined in the 
Pharmaceutical Sciences Department of the University of Salerno, at the 
laboratories of professor B. Maresca, to evaluate antiproliferative activity 
against three cell lines: the transformed human embryonic kidney HEK, the 
human melanoma M14, and the human leukemia monocyte lymphoma U937 
cell lines. The obtained IC50 values are summarized in Table 3.  
 
Table 3. Cytotoxic activity of spiro[imidazo[1,5-c]-thiazole-3,3‘-indoline]-
2‘,5,7(6H,7aH)-trione derivatives 42a-e/45a-e 
 
 IC50 ( M) ±SD
a 






42a H H -CH2C6H5 4.80±0.15 10.64±0.04 3.90±0.01 
42b H H -CH2C6H4(4-CH3) 4.53±0.15 13.27±0.03 5.91±0.02 
42c H H -CH2C6H4(4-Cl) 0.44±0.01 0.53±0.01 0.87±0.01 
42d H H -CH2C6H2(3,4,5-OCH3) 3.80±0.08 4.73±0.02 2.51±0.05 
42e H H 4-dimethylcyclohexyl 4.22±0.07 7.07±0.01 2.61±0.05 
43a CH3 H -CH2C6H5 3.30±0.07 3.88±0.02 2.09±0.04 
43b CH3 H -CH2C6H4(4-CH3) 3.01±0.06 3.39±0.03 2.77±0.02 
43c CH3 H -CH2C6H4(4-Cl) 3.88±0.05 6.65±0.02 3.31±0.04 
43d CH3 H -CH2C6H2(3,4,5-OCH3) 2.04±0.03 2.40±0.02 2.06±0.04 
43e CH3 H 4-dimethylcyclohexyl 16.01±0.05 19.12±0.07 12.48±0.05 
44a Br H -CH2C6H5 8.48±0.09 12.04±0.03 7.58±0.05 




44c Br H -CH2C6H4(4-Cl) 7.13±0.06 7.06±0.05 5.01±0.03 
44d Br H -CH2C6H2(3,4,5-OCH3) 9.31±0.09 11.04±0.02 5.02±0.03 
44e Br H 4-dimethylcyclohexyl >40 >40 >40 
45a H CH3 -CH2C6H5 3.98±0.05 6.37±0.04 2.89±0.03 
45b H CH3 -CH2C6H4(4-CH3) 10.71±0.10 31.79±0.04 16.75±0.02 
45c H CH3 -CH2C6H4(4-Cl) 2.11±0.05 2.47±0.02 2.91±0.01 
45d H CH3 -CH2C6H2(3,4,5-OCH3) 6.01±0.06 7.66±0.23 5.70±0.05 
45e H CH3 4-dimethylcyclohexyl >40 >40 >40 
Doxorubicin 0.9±0.08 1.0±0.05 0.8±0.01 
 
 
Doxorubicin was used as reference cytotoxic agent. The most interesting 
results were obtained with the isatin 42 series. Compound 42c containing a 4-
chlorobenzyl substituent at position N-6 showed an elevated cytotoxic activity 
with IC50 values of 0.44, 0.53, and 0.87 μM in HEK, M14, and U937 cell 
lines, respectively. Compounds 42a, 42b, and 42d, with a diverse 
substituted benzyl group at the N-6 position, retained the cytotoxic activity at 
micromolar concentration on the HEK and U930 cell lines, while they were 
less active in the M14 melanoma cell line. The introduction of an electron-
releasing group as the -CH3 group at C-5‘ position of the indol ring produced 
different effects: while the derivative 43c reduced activity in the three cell 
lines compared to 42c (8-, 12-, and 3-fold, respectively), compounds 43a, 43b, 
and 43d increased their biological effect in all cell lines compared to 42a, 42b, 
and 42d. In particular, these compounds were 2- to 4-fold more potent than the 
corresponding analogues 42 against M14 cell line. 
The introduction at the C-5‘ position of the isatin moiety of an electron-
withdrawing group such as the bromide group caused a reduction of the 
activity of the corresponding analogues 44a, 44b, 44c, and 11d in all cell lines. 




position was tolerated only in the isatin series 42 (compound 42e) even with a 
loss in activity with respect to 42c (8-, 14-, and 4-fold in the three cell lines, 
respectively). Compounds 43e, 44e, and 45e showed a dramatic loss of 
activity. Finally, the derivatives 45a, 45c, and 45d, which incorporate at 
position N-10 a methyl group, retained cytotoxic levels within the micromolar 
range. The same substitution was detrimental for the activity of analogues 45b 
and 45e. 
The preliminary results on cytotoxicity and morphological cellular differences 
after treatment with 42c and 43d (see below) motivated us to study further the 
mode of action of these compounds. We have performed a comparative 
analysis of their effects on growth in immortalized normal thyroid TAD-2 and 
human papillary thyroid carcinoma TPC1 cell lines to establish a safety profile 
of these derivatives. Inhibition of proliferation of both cell lines was measured 
after treatment with 100 nM and 1 μM of 42c and 43d at 48 h. 
Figure 1a shows that at 100 nM, 9c and 10d caused a net decrease in the total 
number of cells in the carcinoma TPC1 cell line (70%and 58%, respectively), 
whereas the percentage of cellular growth inhibition in the TAD-2 cell line 
was only of 10% for 42c and void for 43d (Figure 19b). At 1 μM, both 
compounds were cytotoxic for the TAD-2 cell line. These data seem to 
indicate that at 100 nM, 42c and 43d have a good profile of ―cell selectivity‖. 
Furthermore, the introduction into 42c and/or 43d of a third hydrophobic 
group at the N-10 position appeared to have an important effect upon 
















Figure 19. Effect of 42c and 43d derivatives on cell growth of (a) human 
papillary thyroid carcinoma TPC1 and (b) normal thyroid TAD-2 cell lines 
 
Derivatives 46f-i were 3- to 10-fold less potent than the corresponding 
analogue 42c, though they maintain their activity in the micromolar range 
(IC50 of 2.01-5.01 μM, Table 3). These results are in agreement with those 
found for 45c (IC50 of 2.11-2.91 μM, Table 1), which has a CH3 group at the 




position limits the optimal side chain accommodation in the target, 
independent of their electronic and steric properties. The introduction of acyl 
side chains in N-10 position of 43d led to slight or moderate decreases in the 
cytotoxic activity. Derivatives 47f-i were only 1.5- to 3-fold less active than 
their analogue 10d. These findings imply a lower tolerance of compound 42c 
to structural modification. 
 
Table 4. Cytotoxic Activity of 1’-Acylspiro[(dihydroimidazo[1,5-c]-thiazolo-













HEK M14 U937 
42c H  4-Cl 0.44±0.01 0.53±0.01 0.87±0.01 
46f H -C6H5 4-Cl 3.50±0.02 3.25±0.36 3.12±0.07 
46g H -C6H4(4-CH3) 4-Cl 2.50±0.10 2.08±0.10 2.01±0.15 
46h H -C6H4(4-Cl) 4-Cl 5.01±0.15 3.37±0.37 2.61±0.05 
46i H -CH2CH2CH3 4-Cl 2.01±0.05 2.04±0.34 2.10 ±0.09 
43d CH3  3,4,5-OCH3 2.04±0.03 2.40±0.02 2.06±0.04 
47f CH3 -C6H5 3,4,5-OMe 4.22±0.14 7.84±0.02 4.31±0.02 
47g CH3 -C6H4(4-CH3) 3,4,5-OMe 3.81±0.05 5.95±0.01 2.42 ±0.04 
47h CH3 -C6H4(4-Cl) 3,4,5-OMe 4.71±0.15 8.14±0.02 3.11±0.01 
147i CH3 -CH2CH2CH3 3,4,5-OMe 4.42±0.16 7.40±0.0126 4.10± 0.02 
a





6.4.1 Phase-Contrast Microscopic Analysis of Cell Morphology and 
Apoptosis.  
Figure 20 shows that vehicle-treated M14 cells grew normally, while treatment 
with 42c and 43d impaired their morphology as determined by video time 
lapse microscopy. 
A 10 h treatment with these compounds caused the emergence of round and 
damaged shapes followed by the formation of numerous blebs and a 
progressive detachment from the plastic well (48 h treatment). Treated cells 
displayed a lower number of cell division compared to control cells (Figure 2). 
These modifications were more pronounced and appeared earlier in cell 
cultures treated with 42c than with 43d and were consistent with induction of 
apoptotic cell death.
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 To confirm this observation, we measured caspase-3 
activity. Upon cleavage by upstream proteases in an intracellular cascade, the 










Figure 20. Morphological changes induced by treatment of M14 cell line with 
42c and 43d after 10, 24, and 48 h at IC50 concentration. Cells had a 
doubling time of 19 h in culture (confirmed by cell counts, data not shown). 
 
 The levels of cleaved active subunits of executioner caspase-3 were evaluated 
by Western blotting of M14 cell lysates following 42c (0.1-0.3 μM) and 43d 
(1.0-5.0 μM) treatment for 16 and 24 h (Figure 21a). Compound 43d did not 
lead to any caspase cleavage even at supra-IC50 concentration. 42c increased 
caspase-3 activity after a 16 h exposure. Next, we examined the activation-
mediated cleavage of caspase-3 substrate, poly(ADP-ribose) polymerase 
(PARP), which is a reliable marker of apoptosis (Figure 3b).
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 By use of the 
cysteine protease activity, caspases separate N-terminal DNA-binding domain 
of PARP from its C-terminal catalytic domain (85 kDa) showing that 42c 




suggesting that 9c induced apoptotic cell death in M14 cells. On the contrary, 
after 24 h and at cytotoxic concentration, compound 10d did not induce 




Figure 21. Caspase-3 (a) and PARP (b) cleavages induced for 42c and 43d. 
6.4.2 Cell Cycle Effects and Expression of p53.  
 
On the basis of previous data, we analyzed the effect of 9c and 10d on cell 
cycle progression. The cytometric investigation showed a clear arrest at G2/M 
cell cycle phase of M14 cells treated with 43d (3 μM) for 24 h compared to 
control cells (Figure 22a). Accumulation of cells in the G2 phase increased 
about 47% (p<0.001) with a corresponding decrease of cells in the G0/G1 
phase (down to 20%, p<0.001). Under the same conditions, treatment of M14 
cells with 42c (0.3 and 1 μM) did not show any significant effect on the cell 
cycle progression. The arrest of cell cycle induced by 43d correlated well with 




22b), indicating that cell cycle progression of cells in the G2/M phase was 







Figure 22. Effects of 42c and 43d on the distribution of cell populations. Data 
represent the percentage of cells in each cellular cycle phase (a). Shown is the 





Subsequently, we examined expression of the p53 as key regulator of both 
cell-cycle arrest and cell apoptotic death. Treatment of M14 cells with 
subcytotoxic concentrations of 42c and 43c produced, in both cases, a gradual 
increase of the p53 levels from 24 to 48 h. As observed in Figure 23, this 





Figure 23. Western blot analysis of cytoplasmatic p53 levels in M14 cells 
untreated (K) and treated with 42c (0.3 μM) and 10d (3 μM) after 24 and 48 h. 
 
6.4.3 Inhibition of p53-MDM2 Interaction.  
 
The ability of compounds 9c and 10d to block p53-MDM2 interaction was 
investigated by NMR analysis. Holak et al. have recently described a two-
dimensional N-HSQC based NMR assay to determine the effect of antagonists 
on protein-protein interactions.
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 The method, named AIDA (for antagonist 
induced dissociation assay), provides information on whether an antagonist of 
a protein-protein interaction is strong enough to dissociate the complex and 
whether its mode of action is modulated by denaturation, precipitation, or 
release of a protein in its functional folded state. AIDA requires the use of a 
large protein fragment (larger than 30 kDa) to bind to a small reporter protein 




NMR spectra may suffice for monitoring the states of proteins in complexes 
upon treatment with ligands. Because of the highly flexible nature of the N-
terminal domain of p53, p53-MDM2 complex is suitable for 1D proton NMR 




 side chains of W23 and W53 produce sharp 
lines in the free p53 1Dproton spectrum. On formation of the complex with 
MDM2, W23 signal disappears, since W23, together with the p53 residues 17-
26, comprises the primary binding site for MDM2.
167,168
 Upon binding, these 
residues participate in well-defined structures of large p53-MDM2 complexes, 
whereas W53 is still not structured when p53 is bound to MDM2. The 
observed 1/T2 transverse relaxation rate of the bound W23 in the complexes 
increases significantly, and the broadening of NMR resonances results in the 
disappearance of this signal from the spectra. Figure 8a shows the NMR 
spectrum of the tryptophan residues of the p53-MDM2 complex (only W53 
NHε side chains signal can be detected). After the addition of 42c or 43d to 
the p53-MDM2 complex, the W23 peak appears (Figure 24b and Figure 6c, 
respectively). Nutlin-3 was also used as positive control (Figure 24d), causing 
a complete p53 release.
167
 Both compounds 42c and 43d released p53-MDM2 






Figure 24. One-dimensional proton spectrum of the side chains of tryptophans 




































The p53 tumor suppressor is a sequence-specific transcription factor whose 
inactivation or loss contributes to carcinogenesis. Several in vitro and in vivo 
studies have demonstrated that p53 is involved in growth arrest, genomic 
stability, cell senescence and differentiation while also activating p53 
mediated apoptotic stress responses. Given its role in these fundamental 
process wild-type p53 is an attractive target for pharmacological intervention. 
Identification of small molecules able of reactivating specific p53 roles  turns 
into a main aim for an important part of the scientific community .  
This PhD thesis work presents the obtained results in the searching for small-
molecules able to ―reactive‖ the p53 transcriptional activity. The research was 
based on the identification of  both DNA-damaging agents and compounds 
that modulate p53-MDM2 interaction, a negative regulator of p53 activity and 
stability, and included two projects. The first of them was centered in the 
design and synthesis of carbazole derivatives as DNA- damaging agents. The 
second, more wide,  was based on the valuation of natural product analogues 
designed as both cellular cycle modulators and p53-MDM2 interaction 
inhibitors.  
The first part of project has taken us to the synthesis of new N-[(9H-carbazol-
9-yl)alkyl)]-N,N-(diethyl)amine (serie 1) and 2-(9H-carbazol-9-yl)-N-(2-
(dimethylamino)ethyl)substituted amide (serie 2) derivatives with cytotoxic 
activity in the micromolar range. Due to small structural differences in the 
most active compounds, a rigorous determination of structure-activity 
relationships is not possible right now. Our research on these compounds will 
continue by modifying and developing the most promising cytotoxic active 
compounds.  
The results obtained in the second part of project, in this turn divided in two 
issues, lead to a series of interesting conclusions.  
A synthetic level, we show the wide potentiality of the acid and base 




derivatives to new tricyclic systems: hexahydropyrrolo[1,2-
a][1,3]thiazolo[3,2-d]pyrazine-5,10-dione (structure I) and hexahydropyrrolo 
[1,2-a][1,3]thiazolo[3,4-d]pyrazine- 5,10-dione (structure II). Possible 
reaction pathways for the formation of these structures imply unusual 
oxoindole ring opening. In contrast, the acid promoted intramolecular 
cyclization of isomer 30-prolylspirooxoindolelthiazolidine leads to new 
spirotryprostatin A-inspired derivatives spiroindol-2-one[3,30]hexahydro- 
5,10H-pyrrolo[1,2-a][1,3]thiazolo[3,4-d]pyrazine-5,10-dione (structure III). 
Application of the methodology developed in this work represents a new 
possibility for molecular diversification of oxoindole systems and for the 
development of other biologically useful members of the diketopiperazine 
structural class.  
Among the hexahydropyrrolo[1,2-a][1,3]thiazolo[3,4-d]pyrazine-5,10-dione 
derivatives (structure II), the compounds 23a and 24a showed remarkable 
cytotoxic activity against MCF-7 cell lines at micromolar concentration. 
Moreover, they did not inhibit the cellular cycle, indicating that their 
mechanism of action did not include an interference with the cell cycle 
regulation systems. These compounds may become a promising class of 
cytotoxic agents and further experiments, aimed at defining the target and the 
mechanisms of the growth-inhibitory effect shown by some of these 
molecules are currently underway. 
The design of N-substituted spiro[imidazo[1,5-c]thiazole-3,30-indoline]-
2‘,5,7-trione derivatives lead to more interest compounds. In particular, 
compound (3R,7aR)-6-(4-Chlorobenzyl)-1H-spiro[imidazo[1,5-c]thiazole-
3,3‘-indoline]-2‘,5,7(6H,7aH)-trione (42c) showed high efficacy in HEK-293 
(kidney), M-14 (melanoma), and U937 (leukemia) human cell lines with IC50 
values of 0.44, 0.53, and 0.87 μM, respectively. The derivative containing a 
trimetoxybenzyl group at N-6 position, 43d, was 3- to 5-fold less cytotoxic in 




of 42c. Preliminary studies on the induction of apoptosis and cell cycle 
progression in M14 cell line confirmed a different behavior of these 
compounds. Thus, compound 42c induced apoptotic cell death after 24 h of 
treatment at cytotoxic concentration, while 43d did not induce apoptotic death 
in the same period of time. On the other hand, 43d markedly prolonged the 
G2 phase, causing a delay of cell cycle progression in responsive cells, while 
treatment with 42c did not alter the normal course of cell cycle. However, 
both compounds induce a time-dependent increment of p53 expression, 
indicating that the activity profiles of these derivatives might be regulated by 
this protein. NMR investigation performed on both compounds demonstrated 
that the ability of these compounds to block p53-MDM2 interaction caused 
release of p53. Taken together, that chemical modification at the pyrrolidine 
moiety of spirooxoindole system is an effective approach to study the 
modulation of p53 activity through p53-MDM2 inhibition. 
These preliminary results support the hypothesis of which it is possible the 
reactivation of p53 by small molecules, validating their potential therapeutic 
value. In addition, these small molecules will can represent important tools in 
the identification of pathways and/or factors governing the decision between 
apoptosis and growth arrest/DNA repair induced by p53. 
 Further experiments aimed both to identify more potent and selective 
spirothiazolidin-based derivatives and to better understand the mechanisms of 
































8. EXPERIMENTAL SECTION: 
 
8.1. Materials and methods 
 
Reagents and solvents were purchased from commercial suppliers and used as 
received. Analytical TLC was performed on plates coated with a 0.25 mm 
layer of Silica Gel 60 F254 Merck and preparative TLC on 20 _ 20 cm glass 
plates coated with a 0.5 mm layer of silica gel PF254 Merck. Silica Gel 60 
(300–400 mesh, Merck) was used for flash chromatography. Melting points 





NMR spectra were recorded at 400 and 100 MHz, respectively. Chemical 
shifts are reported in alues (ppm) relative to internal Me4Si and J values 
are reported in hertz. Mass spectra were measured by the ES method. 
Elemental analyses were carried out with C, H-analyzer. DMEM, fetal bovine 
serum, glutamine, penicillin, streptomycin, Hepes, sodium pyruvate and PBS 
were from Bio Whittaker (Caravaggio, BG, Italy). MTT was purchased from 
SIGMA (Milan, Italy). 
 
8.1.1. NMR spectroscopy 
NMR experiments were performed on a Varian Mercury 400 MHz 
spectrometer at 298 K. NMR samples were prepared by dissolving each 
compound (about 5 mM) in 0.6 ml of CDCl3. 2D NOESY spectra of 
compounds 25a, 28b, 30a, 30b and 31a, 31b were recorded in the phase-
sensitive mode, data block sizes were 2048 addresses in t2 and 512 equidistant 
t1 values. Before Fourier transformation, the time domain data matrixes were 
multiplied by shifted sin2 functions in both dimensions. A mixing time of 400 






8.1.2. Protein Expression and Purification for NMR Study.  
The recombinant human MDM2 (residues 1-118) was overexpressed in E. coli 
BL21(DE3) RIL using the pET-46Ek/LIC vector (Novagen). Cells were 
grown at 37 _C and induced with 1 mM IPTG at an OD600 of 0.7. The protein 
was purified and renatured from inclusion bodies as described.28 The refolded 
protein was applied on butyl Sepharose 4 Fast Flow (Amersham) and then 
purified on a Sephadex G-75. The recombinant human p53 protein (residues 1-
312) was overexpressed at 37 _C in E. coli BL21 (DE3) RIL using a pET-
46Ek/LIC vector (Novagen) modified with N-terminal His-tag. The protein 
was purified under denaturing conditions using a NiNTA (Qiagen) column, 
refolded, and further purified using a gel filtration on Sephadex G-75 as 
previously described.28 Complexes were made by mixing p53 andMDM2in a 
molar ratio of 1:2. The excess ofMDM2 was then removed by gel filtration on 
Sephadex G-75. 
 
8.1.3. NMR Study of p53-MDM2 Interaction.  
NMR spectra were acquired at 25 °C on a Varian Unity INOVA 700 MHz 
spectrometer equipped with a cryoprobe. Typically, NMR samples contained 
up to 0.1 mM protein in 50 mMKH2PO4, 50 mM Na2HPO4, 150 mM NaCl, 
pH 7.4, 5 mM DTT, 0.02% NaN3. Water suppression was carried out by 
gradient echo.30 NMR data were processed using the Bruker program BioSpin 
3.0. For NMR ligand binding experiments, 600 μL of the protein sample 
containing 10% D2O, at ∼0.1 mM, and a 10 mM stock solution of each 
compound in DMSO-d6 were used in all experiments. The final molar ratio 








8.1.4. Computational data 
Molecular modeling and graphics manipulations were performed using the 
Insight II software package (Accelrys, San Diego, CA). The 3D structures of 
the compounds were constructed using the module Builder of Insight II 
program and then optimized using minimization steps (conjugate gradient 
method), in vacuo, using the CVFF force field20 in Insight II/Discover 
software packages. MD simulations were performed at 500 K period (time 
step = 1 fs). MD results were analyzed with the Analysis module of Insight II. 
 
8.1.5. Statistical Analysis.  
Data were analyzed using Prism 4.0 (Graph Pad Software, Inc.). Results are 
expressed as the mean ( SEM. All statistical differences were evaluated by a 
two tailed Student‘s t test and one way ANOVA. P values less than 0.05 were 
considered statistically significant. 
 
8.1.6. Crystallographic analysis 
A suitable crystal of 21 (0.04 _ 0.6 _ 0.04 mm) was selected and mounted on a 
glass fibre. The diffraction data were collected at 100 K with graphite 
monochromatized Mo Ka radiation (k = 0.71069 A, 2hmax 654.52_, u and x 
scan mode) on a Rigaku AFC7S diffractometer equipped with a Mercury CCD 
detector and corrected for Lorentz, polarization and absorption effects. The 
data collection was performed with a detector to crystal distance D = 414 mm 
using an oscillation angle of Du = 0.5_ and consisted of 892 images. It 
covered a resolution range of d = 26.76–0.80 A. Intensity data were corrected 
for absorption.21 Lattice constants and crystal orientation were obtained using 
1D FFT with DPS algorithm, 22 the number of reflections used was 970 with a 
refinement of 30 best directions and lengths. The structure was solved by 
direct methods using SIR9223 and the refinement, realized by SHELXL97,24 




hydrogens included on calculated positions, riding on their parent atoms and 
then refined isotropically. A total of 514 parameters were refined. Maximum 
and minimum residual density were 0.85 and _0.45 e/A3. Final disagreement 
indices: R1 = 0.0578 for 3556 reflections with Fo >4r(Fo) and wR2 = 0.1711 
for all 8860 data. ORTEP drawings were prepared by means of the program 
ORTEP32.25 
 
8.2. General Procedure for the Synthesis of the N-[(9H-carbazol-9-
yl)alkyl)]-N,N-(diethyl)amine (1a, 1b, 1c).  
1,2-dibromoethane, or 1,3-dibromopropane, or 1,4-dibromobutane (0.20 
mmol) was added to a solution of carbazole (0.10 mmol) in toluene (60 mL). 
After stirring at room temperature for 10 minutes, a basic solution of NaOH 
50% (44mL) containing benzyltriethylamoniobromide (0.03 mmol) was 
added. The reaction mixture was then stirred at room temperature for 20 h. 
Solvent was evaporated and the residue was dissolved into dichloromethane. 
The organic solution was washed with water (3 x 100 mL), dried over Na2SO4, 
and evaporated in vacuo. The residues were washed with n-hexane to remove 
the excess of dibromoalkane. The achieved compounds were crystallized with 
n-hexane to give white solids. The crystallized compounds were dissolved in 
DMF. and  N,N‘-diethylamine (0.13 mmol) and Cs2CO3 (0.13 mmol) were 
added. The mixture was stirring at room temperature for 18 h. The mixture 
was then cooled to ambient temperature and solvent was removed in vacuo. 
The residue was dissolved in dichloromethane and washed with water (3 x 100 
mL). Flash chromatography on silica gel, using ethyl acetate/n-hexane in 1/4 








 N-[(9H-carbazol-9-yl)ethyl)]-N,N-(diethyl)amine (1a). 
Brown oil. (68%). mp 132°C. 
1
H NMR (300 MHz, CDCl3) δ 1.36 (t, 6H, 
CH3); 3.17 (q, 4H, CH2 ethyl); 3.32 (t, 2H, CH2 ethyl); 5.02 (t, 2H,CH2 ethyl); 
7.26 (t, 2H, H-2‘ and H-7‘); 7.47 (t, 2H, H-3‘ and H-6‘); 7.61 (d, 2H, J = 8.0 
Hz, H-1‘ e H-8‘); 8.06 (d, 2H, H-4‘ e H-5‘). FAB-MS m/z calcolated fof 
C18H22N2, 266.18, found, 266.21. 
 
 N-[(9H-carbazol-9-yl)propyl)]-N,N-(diethyl)amine (1b). 
Brown oil. (70%). mp 144 °C. 
1
H NMR (300 MHz, CDCl3) δ 1.26 (t, 6H, 
CH3); 1.85-1.91 (m, 2H, CH2 ethyl); 3.07 (t, 2H, CH2 ethyl); 3.29 (q, 4H, CH2 
ethyl); 3.78 (t, 2H, CH2 ethyl); 7.26 (t, 2H, H-2‘ and H-7‘); 7.49 (t, 2H, H-3‘ e 
H-6‘); 7.64 (d, 2H, J = 8.0 Hz, H-1‘ e H-8‘); 8.08 (d, 2H, H-4‘ and H-5‘). 
FAB-MS m/z calcolated for C18H21N2, 265.18, found, 265.25. 
 
 N-[(9H-carbazol-9-yl)butyl)]-N,N-(diethyl)amine (1c). 
Brown oil. (73%). mp 149 °C. 
1
H NMR (300 MHz, CDCl3) δ 1.26 (t, 6H, 
CH3); 1.42-1.48 (m, 2H, CH2 ethyl); 1.85-1.91 (m, 2H, CH2 ethyl); 3.07 (t, 
2H, CH2 ethyl); 3.29 (q, 4H, CH2 ethyl); 3.78 (t, 2H, CH2 ethyl); 7.26 (t, 2H, 
H-2‘ and H-7‘); 7.49 (t, 2H, H-3‘ and H-6‘); 7.64 (d, 2H, J = 8.0 Hz, H-1‘ e H-
8‘); 8.08 (d, 2H, H-4‘ and H-5‘). FAB-MS m/z calcolated for C20H27N2, 
295.22, found, 295.26. 
 
8.3. General Procedure for the Synthesis of the N-[(9H-carbazol-9-
yl)alkyl)]-N,N-(diethyl)amine (2, 3, 4).  
Dimethoxytetrahydrofurane (2,5 mmol) in glacial acetic acid (1 mL) was 
added to a solution in glacial acetic acid (8 mL) of L-Phe-OEt, or L-Ala-OEt, 
or L-Gly-OEt (1 mmol) and heated to reflux temperature for 4 h, in nitrogen 
atmosphere. Solvent was evaporated and the residue was dissolved into 




silica gel, using ethyl acetate/n-hexane in 2/3 ratio as eluent, yielded the 
correspondent derivatives 2, 3, 4. Compounds 2, or 3, or 4 were dissolved in a 
mixture MeOH/H2O 1/1 ratio (10 mL) and LiOH (3.0 mmol) was added. The 
reaction mixture was then stirred at room temperature for 10 h and then the 
MeOH was removed in vacuo. The water was treated with citric acid and 
extracted with dichloromethane (3 x 100 mL). The organic solution was dried 
over Na2SO4, and evaporated in vacuo. 
 
8.4. General Procedure for the Synthesis of the 2-(9H-carbazol-9-yl)-N-[2-
aminoethyl]substituted-amide derivatives (2a, 2b, 3a, 3b, 4a, 4b). 
 HOBt (1,3 mmol), HBTU (1,3 mmol) e DIPEA (2,6 mmol) were added to a 
solution of compound 2‘, or 3‘, or 4‘  (1.0 mmol) in DCM/DMF 10/3 ratio (13 
mL). After stirring at room temperature for 10 minutes, a solution in DCM of 
corresponding amines (N,N‘-dimethyl-ethylene-diamine, N-ethyl-morpholine 
a-b)  (1,3 mmol) was added. The reaction mixture was then stirred at room 
temperature for 12 h. Solvent was evaporated and the residue was dissolved 
into dichloromethane. The organic solution was washed with an aqueous 
solution of NaHCO3 (3 x 100 mL), dried over Na2SO4, and evaporated in 
vacuo. Flash chromatography on silica gel, using dichloromethane/methanol in 
9/1 ratio as eluent, yielded the correspondent final derivatives. The achieved 
compounds were crystallized with MeOH to give white solids.  
 
2-(9H-carbazol-9-yl)-N-(2-(dimethylamino)ethyl)acetamide (2a). 
White solid. (71%). mp 153 °C. 
1
H NMR (300 MHz, CDCl3) δ 2.81 (s, 
6H,CH3); 3.15 (t, 2H,CH2 ethyl); 3.67 (t, 2H, CH2 ethyl); 4.97 (s, 2H, H-2); 
7.21 (t, 2H, H-2‘ and H-7‘); 7.39-7.43 (m, 4H, H-1‘, H-3‘, H-6‘ and H-8‘); 






 2-(9H-carbazol-9-yl)-N-(2-morpholinoethyl)acetamide (2b). 
White solid. (67%). mp 164 °C. 
1
H NMR (300 MHz, CDCl3) δ 1.96 (t, 4H, 
CH2 morpholin); 2.11 (t, 2H,CH2 ethyl); 2.98 (t, 4H, CH2 morpholin); 3.14 (t, 
2H, CH2 ethyl); 4.95 (s, 2H, H-2); 6.18 (s, 1NH); 7.23 (t, 2H, H-2‘ and H-7‘); 
7.31 (t, 2H, H-3‘ and H-6‘); 7.48 (d, 2H, J = 8.0 Hz, H-1‘ and H-8‘); 8.17 (d, 
2H, H-4‘ and H-5‘). FAB-MS m/z calcolated for C20H23N3O2, 337.18, found, 
337.22. 
 
 2-(9H-carbazol-9-yl)-N-(2-(dimethylamino)ethyl) propanamide (3a). 
White solid. (69%). mp 172 °C. 
1
H NMR (300 MHz, CDCl3) δ 1.77 (d, 3H, J 
= 7.2 Hz, H-3); 1..86 (s, 6H, CH3); 2.06-2.25 (m, 2H, CH2 ethyl); 3.17-3.22 
(m, 1H,CH2 ethyl); 3.28-3.38 (m, 1H,CH2 ethyl);  5.33 (q, 1H, H-2); 6.33 (s, 
1NH); 7.26 (t, 2H, H-2‘ and H-7‘); 7.45 (t, 2H, H-3‘ and H-6‘); 7.53 (d, 2H, J 
= 8.0 Hz, H-1‘ and H-8‘); 8.09 (d, 2H, H-4‘ and H-5‘). FAB-MS m/z 
calcolated for C19H23N3O, 309.18, found, 309.26. 
 
 2-(9H-carbazol-9-yl)-N-(morpholinoethyl)propanamide (3b). 
White solid. (64%). mp 179 °C.
1
H NMR (300 MHz, CDCl3) δ 1.77 (d, 3H, J = 
7.2 Hz, H-3); 2.01 (t, 4H,CH2 morpholin); 2.10 (t, 1H,CH2 ethyl); 2.19 (t, 
1H,CH2 ethyl);  2.92-3.11 (m, 5H, CH2 morpholin and CH2 ethyl); 3.18 (t, 1H, 
CH2 ethyl); 5.31-5.34 (m, 1H, H-2); 6.36 (s, 1NH); 7.23 (t, 2H, H-2‘ and H-
7‘); 7.34 (t, 2H, H-3‘ and H-6‘); 7.40 (d, 2H, J = 8.0 Hz, H-1‘ and H-8‘); 8.09 





White solid. (73%). mp 203 °C. 
1
H NMR (300 MHz, CDCl3) δ 2.48 (s, 3H, 




ethyl); 3.45 (t, 1H, Ha-3); 3.67 (dd, 1H, J‘ = 4.0 Hz, J’’ = 14.4 Hz Hb-3);  4.13 
(s, 1NH); 5.66 (dd, 1H, J‘ = 4.0 Hz, J’’ = 8.0 Hz H-2);  6.81-6.94 (m, 5H, 
aryl); 7.17-7.36 (m, 6H, H-1‘, H-2‘ H-3‘, H-6‘, H-7‘ and H-8‘); 8.05 (d, 2H, 
H-4‘ e H-5‘). FAB-MS m/z calcolated for C25H27N3O, 385.22, found, 385.26. 
 
2-(9H-carbazol-9-yl)-N-(2-morpholinoethyl)-3-phenylpropanamide (4b). 
White solid. (65%). mp 216 °C. 
1
H NMR (300 MHz, CDCl3) δ 1.88 (t, 
4H,CH2 morpholin); 2.14 (t, 1H,CH2 ethyl); 2.23 (t, 1H,CH2 ethyl);  3.02-3.16 
(m, 5H, CH2 morpholin and CH2 ethyl); 3.36-3.41 (m, 1H, CH2 ethyl); 3.50 (t, 
1H, Ha-3); 3.91 (dd, 1H, J‘ = 4.0 Hz, J’’ = 14.4 Hz Hb-3);  5.34 (dd, 1H, J‘ = 
4.0 Hz, J’’ = 8.0 Hz H-2); 6.39 (s, 1NH); 6.76-6.92 (m, 2H, aryl); 8.06 (d, 2H, 




8.5. General procedure for the synthesis of spirooxoindolethiazolidine ethyl 
ester derivatives (6a,b–12a,b) and spirooxoindolethiazolidine carboxylic acid 
(29a,b–32a,b) derivatives 
The reactions were carried out in a Milestone CombiChem Microwave 
Synthesizer. All irradiation process, rotation of the rotor, irradiation time, 
temperature, and power were monitored with the ‗easyWAVE‘ software 
package. Temperatures were monitored with the aid of an optical fiber inserted 
into one of the reaction vessels. NaHCO3 (10 mmol) and the corresponding 
isatin derivatives (4-8, 12 mmol) were added to a solution of L-Cys-OEt or L-
Cys-OH (10 mmol) in methanol (100 mL) and the suspension was irradiated at 
300Wuntil 65 °C was reached. The reaction mixture was held at this 
temperature for 45 min and then cooled rapidly to room temperature. Then the 




carboxylic acid derivatives (33-37) were purified by flash chromatography 
using EtOAc as eluent system, while the corresponding ethyl ester residues 
(9-13) were dissolved in CH2Cl2 and washed with water (3 x 50 mL). The 
combined organic layer was dried over anhydrous sodium sulfate, filtered, and 
concentrated. These compounds were used in the next reaction without further 
purification as diasteroisomeric mixtures. 




H NMR (400 MHz, CDCl3)  1.36 (6H, t, CH3), 3.30–3.33 and 
3.35–3.41 (2H, m, H-5‘a), 3.62–3.67 and 3.91–3.95 (2H, m, H-5‘b), 4.27 (4H, 
q, CH2CH3), 4.48–4.51 and 4.68–4.72 (2H, m, H-40), 6.81 (2H, d, J = 8.0 Hz, 
H-4), 7.11 (2H, t, H-5), 7.34 (2H, t, H-6), 7.48 (2H, d, J = 8.0, H-7), 8.43 (2H, 
s, NH). ES-MS m/z: Calculated for C13H14N2O3S: 278.07. Found: 278.13. 
 




H NMR (400 MHz, CDCl3)  1.36 (6H, t, CH3), 2.21 (6H, s, 
CH3), 3.27–3.31 and 3.38–3.42 (2H, m, H-5‘a), 3.65–3.68 and 3.89–3.91 (2H, 
m, H-5‘b), 4.25 (4H, q, CH2CH3), 4.43–4.45 and 4.61–4.64 (2H, m, H-40), 
6.77 (2H, d, J = 8.0 Hz, H-7), 7.38 (2H, d, J = 8.0 Hz, H-6), 7.45 (2H, s, H-4), 
8.70 (2H, s, NH). ES-MS m/z: Calculated for C14H16N2O3S: 292.09. Found: 
292.13. 
 




H NMR (400 MHz, CDCl3)  1.36 (6H, t, CH3), 3.29–3.34 and 
3.41–3.46 (2H, m, H-5‘a), 3.70–3.75 and 3.92–3.94 (2H, m, H-5‘b), 4.25 (4H, 




H-7), 7.39 (2H, d, H-6), 7.46 (2H, s, H-4), 7.78 (2H, s, NH). ES-MS m/z: 
Calculated for C13H13BrN2O3S: 355.98. Found: 356.03. 




H NMR (400 MHz, CDCl3)  1.36 (6H, t, CH2CH3), 3.22 (6H, s, 
CH3), 3.39–3.41 and 3.45–3.49 (2H, m, H-5‘a), 3.81–3.85 and 3.94–3.97 (2H, 
m, H-5‘b), 4.24 (4H, q, CH2CH3), 4.48–4.50 and 4.69–4.72 (2H, m, H-40), 
6.82 (2H, d, J = 8.0 Hz, H-7), 7.11 (2H, t, H-6), 7.33 (2H, d, J = 8.0 Hz, H-4), 
7.48 (2H, t, 5H). ES-MS m/z: Calculated for C14H16N2O3S: 292.09. Found: 
292.13. 
 
(3R,4’R) and (3S,4’R) 2-oxospiro[indoline-3,20-thiazolidine]- 40-
carboxylic acid (33a,b) 
Oil (68%); 
1
H NMR (400 MHz, CDCl3)  3.24–3.28 and 3.37–3.42 (2H, m, 
H-5‘a), 3.63–3.65 and 3.82–3.84 (2H, m, H-5‘b), 4.26–4.28 and 4.44–4.47 
(2H, m, H-40), 6.81 (1H, d, J = 8.0 Hz, H-4), 7.11 (1H, t, H-5), 7.34 (1H, t, H-
6), 7.48 (1H, d, J = 8.0 Hz, 7-H), 8.43 (1H, s, NH). ES-MS m/z: Calculated for 
C11H10N2O3S: 250.04. Found: 250.09. 
 
 
(3R,4’R) and (3S,4’R) 5-methyl-2-oxospiro[indoline-3,20- 
thiazolidine]-4’-carboxylic acid (34a,b) 
Oil (61%); 
1
H NMR (400 MHz, CD3OD)  2.24 (6H, s, CH3); 3.26–3.29 and 
3.34–3.38 (2H, m, H-5‘a), 3.65–3.68 and 3.81–3.85 (2H, m,  H-5‘b), 4.28–
4.30 and 4.45–4.49 (2H, m, H-40), 6.79 (2H, d, J = 8.0 Hz, H-7), 7.36 (2H, d, 
H-6), 7.48 (2H, s, H-4), 8.83 (2H, s, NH). ES-MS m/z: Calculated for 





(3R,4’R) and (3S,4’R) 5-bromo-2-oxospiro[indoline-3,20-thiazolidine]-4’-
carboxylic acid (35a,b) 
Oil (64%); 
1
H NMR (400 MHz, CD3OD) 3.23–3.25 and 3.38–3.41 (2H, m, 
H-5‘a), 3.64–3.67 and 3.82–3.85 (2H, m, H-5‘b), 4.26–4.28 and 4.48–4.50 
(2H, m, H-40), 6.78 (2H, d, J = 8.0 Hz, H-7), 7.15 (2H, d, H-6), 7.33 (2H, s, 
H-4), 8.49 (2H, s, NH). ES-MS m/z: Calculated for C11H9BrN2O3S: 329.17. 
Found: 329.26. 
 
(3R,4’R) and (3S,4’R) 1-methyl-2-oxospiro[indoline-3,20-thiazolidine]-4’-
carboxylic acid (36a,b) 
Oil (66%); 
1
H NMR (400 MHz, CD3OD)  3.18 (6H, s, CH3); 3.26–3.28 and 
3.37–3.40 (2H, m, H-5’a), 3.68–3.71 and 3.84–3.86 (2H, m, H-5’b), 
4.234.26 and 4.45–4.47 (2H, m, H-40), 6.86 (2H, d, J = 8.0 Hz, H-7), 7.18 
(2H, t, H-6), 7.41 (2H, d, J = 8.0 Hz, H-4), 7.49 (2H, t, H-5). ES-MS m/z: 
Calculated for C12H12N2O3S: 264.06. Found: 264.14. 
 
 
8.6. General procedure for the synthesis of 3-ethyl-10a-(substituted) 
phenyl-5,10-dioxooctahydro-5H-pyrrolo[1,2-a][1,3]thiazolo[3,2-d]pyrazine-
3-carboxylate (19–21) and 3-ethyl-3-(substituted)-phenyl-5,10-
dioxohexahydro-5H-pyrrolo[1,2-a][1,3]thiazolo[3,4-d]pyrazine-3-
carboxylate (26a–b, 27a, 28a–b) 
To a solution of the corresponding spirooxindolthiazolidine ethyl esters (9a,b–
12a,b 3 mmol) in dichloromethane (25 mL), N-Boc-Pro (1.1 equiv), DIC (1.2 
equiv), HOBt (1.2 equiv), and DIPEA (2.4 equiv) were successively added. 
Stirring was continued at room temperature for 4 h. Afterward, the reaction 
mixture was diluted with dichloromethane (20 mL), and the resulting solution 




25 mL), and water (2 x 25 mL), dried over Na2SO4, and evaporated to dryness. 
Flash chromatography of the residues, using different eluent systems, yielded, 
in each case, the correspondent 30-(N-Boc)prolyl derivatives as 
diasteroisomeric mixture (13a,b–16a,b), which were not separated in this step. 
A solution of derivatives  13a,b or 14a,b or 15a,b or 16a,b (1 mmol) in 
CH2Cl2 (10 mL), was treated with trifluoroacetic acid (5 mL) and stirred at 
room temperature. After 2 h, TEA was added until pH 7 and the resulting 
mixtures were washed with water (3 x 25 mL), dried over Na2SO4, evaporated 
to dryness, and purified and separated by flash column chromatography using 
different eluent systems to yield the title compounds. 
 
(3R,5aS,10aS) 3-Ethyloxycarbonyl-10a-(2’-amino)-phenyl-5,10-
dioxooctahydro-5H-pyrrolo [1,2-a][1,3] thiazolo[3,2-d]pyrazine (23) 
FC in ethyl acetate/n-hexane 3/2. White solid (40%); mp 140–141 °C; 
D_30.1 (c 0.1 in CHCl3); 
1
H NMR (400 MHz, CDCl3)  1.33 (3H, t, 
CH2CH3), 1.81–1.86 (1H, m, H-7a), 1.96–2.04 (1H, m, H-7b), 2.21–2.29 (2H, 
m, H-6), 2.96 (1H, t, H-2a), 3.24 (1H, dd, J = 6.4 and 12.4 Hz, H-2b), 3.42–
3.47 (1H, m, H-8a), 3.59–3.66 (1H, m, H-8b), 4.12 (1H, t, H-5a), 4.27 (1H, q, 
CH2CH3), 4.31 (1H, q, CH2CH3), 4.83 (1H, dd, J = 6.0 and 10.4 Hz, H-3), 
6.70 (1H, d, J = 7.2 Hz, H-30), 6.75 (1H, t, H-50), 7.16 (1H, t, H-40), 8.02 
(1H, d, J = 7.2 Hz, H-60); 13C NMR (100 MHz, CDCl3)  14.3 (CH3), 23.4 
(C-6), 27.6 (C-7), 31.8 (C-2), 46.9 (C-8), 59.3 (C-5a), 62.2 (CH2), 65.4 (C-3), 
82.5 (C-10a), 117.1 (C-40), 118.0 (C-60), 127.7 (C-50), 128.5 (C-10), 130.4 
(C-30), 145.7 (C-20), 164.3, 166.7, 168.8 (C=O). Anal. Calculated for 
C18H21N3O4S: C, 57.58; H, 5.64; N, 11.19; S, 8.54. Found: C, 57.41; H, 5.59; 





(3R,5aS,10aS) 3-Ethyloxycarbonyl-10a-(2’-amino-5,10 methyl)- phenyl-
5,10-dioxooctahydro-5H-pyrrole[1,2-a][1,3]thiazole[3,2-d]-pyrazine (24) 
FC in ethyl acetate/n-hexane 3/2. White solid (41%); mp 159–161 °C; 25D -
24.9 (c 0.12 in CHCl3); 
1
HNMR (400 MHz, CDCl3)  1.32 (3H, t, CH2CH3), 
1.78–1.85 (1H, m, H-7a), 1.95–2.01 (1H, m, H-7b), 2.23–2.28 (2H, m, H-6), 
2.27 (3H, s, CH3–50), 2.97 (1H, t, H-2a), 3.24 (1H, dd, J = 6.4 and 12.4 Hz, 
H-2b), 3.42–3.48 (1H, m, H-8a), 3.60–3.67 (1H, m, H-8b), 4.08 (1H, t, H-5a), 
4.25 (1H, q, CH2 CH3), 4.33 (1H, q, CH2 CH3), 4.82 (1H, dd, J = 6.0 and 
10.4 Hz, H-3), 6.63 (1H, d, J = 8.0 Hz, H-30), 6.98 (1H, d, H-40), 7.84 (1H, s, 
H-60); 13C NMR (100 MHz, CDCl3)  14.3 (CH3), 23.6 (C-6), 25.3(CH3), 
27.9 (C-7), 31.5 (C-2), 46.7 (C-8), 59.5 (C-5a), 62.4 (CH2), 65.8 (C-3), 81.8 
(C-10a), 120.2 (C-30), 122.4 (C-10), 125.6 (C-40), 128.3 (C-50), 131.1 (C-
60), 144.1 (C-20), 164.2, 166.5, 168.9 (C=O). Anal. Calculated for 
C19H23N3O4S: C, 58.59; H, 5.95; N, 10.79; S, 8.23. Found C, 58.32; H, 5.51; 






FC in dichloromethane/acetone 95/5. White solid (45%); mp 195–196 °C; 25D 
-27.1 (c 0.1 in CHCl3); 1HNMR (400 MHz, CDCl3)  1.34 (t, 3H, CH2CH3), 
1.81–1.88 (1H, m, H-7a), 1.98–2.04 (1H, m, H-7b), 2.26–2.30 (2H, m, H-6), 
2.97 (1H, t, H-2a), 3.26 (1H, dd, J = 6.0 and 11.6 Hz, H-2b), 3.45–3.49 (1H, 
m, H-8a), 3.59–3.66 (1H, m, H-8b), 4.14 (1H, t, H-5a), 4.22 (1H, q, CH2 
CH3); 4.33 (1H, q, CH2 CH3), 4.83 (1H, dd, J = 6.0 and 10.8 Hz, H-3), 6.58 
(1H, d, J = 8.4 Hz, H-30), 7.24 (1H, d, H-40), 8.16 (1H, s, H-60); 13C NMR 




8), 59.4 (C-5a), 62.4 (CH2), 65.6 (C-3), 81.9 (C-10a), 116.1 (C-50), 119.5 (C-
30), 122.7 (C-10), 129.8 (C-40), 133.1 (C-60), 145.1 (C-20), 164.1, 166.6, 
168.5(C=O). Anal. Calculated for C18H20BrN3O4S: C, 47.58; H, 4.44; Br, 




FC in ethyl acetate/n-hexane 3/2. Oil (9%); 
25
D -71.2 (c 0.1 in CHCl3); 
1
H 
NMR (400 MHz, CDCl3)  1.24 (3H, t, CH2CH3), 1.53–1.61 (1H, m, H-7a), 
1.85–1.93 (1H, m, H-7b), 2.38–2.41 (2H, m, H-6), 3.03–3.09 (2H, m, H-1), 
3.46–3.52 (1H, m, H-8a), 3.62–3.68 (1H, m, H-8b), 3.96–4.02 (1H, m, H-5a), 
4.22–4.28 (2H, m, CH2 CH3), 5.13 (1H, d, J = 5.1 Hz, H-10a), 6.70 (1H, t, J = 
8.0 Hz, H-50), 6.79 (1H, d, J = 8.0 Hz, H-30), 6.85 (1H, d, H-60), 7.12 (1H, t, 
H-40); 13C NMR (100 MHz, CDCl3) 13.7 (CH3), 21.0 (C-7), 28.5 (C-6), 
31.7 (C-1), 46.1 (C-8), 60.1 (C-5a), 61.2 (CH2), 62.0 (C-10a), 63.9 (C-3), 
118.0 (C-30), 119.5 (C-50), 122.6 (C-10), 128.4 (C-40), 130.9 (C-60), 149.8 
(C-20), 164.8, 166.7, 169.6 (C=O). Anal. Calculated for C18H21N3O4S: C, 
57.58; H, 5.64; N, 11.19; S, 8.54. Found: C, 57.42; H, 5.49; N, 11.27; S, 8.59. 
 
(3S,5aS,10aR) 3-Ethyloxycarbonyl-3-(2’-amino)phenyl-5,10-
dioxooctahydro-5H-pyrrolo[1,2-a][1,3]thiazolo[3,4-d] pyrazine (26b) 
FC in ethyl acetate/n-hexane 3/2. Oil (24%); 
25
D -152.5 (c 0.11 in CHCl3); 
1
H NMR (400 MHz, CDCl3)  1.32 (3H, t, CH2CH3), 1.63–1.71 (1H, m, H-
7a), 1.87–1.92 (1H, m, H-6b), 2.31–2.35 (2H, m, H-7), 3.02–3.11 (2H, m, H-
1), 3.28–3.33 (1H, m, H-8a), 3.77–3.82 (1H, m, H-8b), 4.20–4.28 (3H, m, H-
5a, CH2CH3), 4.83 (1H, d, J = 5.2 Hz, H- 10a), 6.66 (1H, t, H-50), 6.71 (1H, 
d, J = 8.0 Hz, H-30); 6.78 (1H, d, J = 8.0 Hz, H-60), 7.12 (1H, t, H-40); 13C 




45.7 (C-8), 61.9 (C-5a), 62.1 (CH2), 62.8 (C-10a), 63.7 (C-3), 118.0 (C-30), 
119.5 (C-50),123.4 (C-10), 127.4 (C-40), 131.6 (C-60), 150.6 (C-20), 163.9, 
166.9, 168.7 (C=O). Anal. Calculated for C18H21N3O4S: C, 57.58; H, 5.64; N, 





FC in ethyl acetate/n-hexane 3/2. Oil (23%); 
25
D - 66.7 (c 0.12 in CHCl3); 
1HNMR (400 MHz, CDCl3)  1.29 (3H, t, CH2CH3), 1.78–1.82 (1H, m, 7a-
H), 1.92–2.01 (1H, m, 7b-H), 2.22 (3H, s, CH3), 2.27–2.30 (2H, m, H-6), 
3.12–3.18 (2H, m, H-1), 3.42–3.46 (1H, m, H-8a), 3.69–3.74 (1H, m, H-8b), 
4.00 (1H, t, H-5a), 4.21 (2H, q, CH2CH3), 5.12 (1H, d, J = 5.2 Hz, H-10a), 
6.62 (1H, d, H-30), 6.64 (1H, s, H-60), 6.98 (1H, d, J = 8.0 Hz, H-40); 13C 
NMR (100 MHz, CDCl3)  14.5 (CH3), 20.8 (C-7), 23.9 (CH3), 28.3 (C-6), 
32.9 (C-2), 45.9 (C-8), 61.0 (C-5a), 62.5 (CH2), 63.6 (C-10a), 64.8 (C-3), 
119.8 (C-30), 126.7 (C-40), 129.4 (C-60), 130.1 (C-50), 146.3 (C-20), 163.8, 
166.4, 168.1 (C=O). Anal. Calculated for C19 H23N3O4S: C, 58.59; H, 5.95; N, 




FC in dichloromethane/acetone 95/5. Oil (8%); 
25
D - 69.2 (c 0.2 in CHCl3); 
1
HNMR (400 MHz, CDCl3) 1. 30 (3H, t, CH2CH3), 1.79– 1.83 (1H, m, H-
7a), 1.90–1.99 (1H, m, H-7b), 2.29–2.34 (2H, m, H-6), 3.11–3.20 (2H, m, H-
1), 3.46–3.49 (1H, m, H-8a), 3.62–3.68 (1H, m, H-8b), 3.99 (1H, t, H-5a), 4.23 
(2H, m, CH2CH3), 5.14 (1H, d, J = 5.2 Hz, H-10a), 6.60 (1H, d, J = 8.0 Hz, 




 14.4 (CH3), 23.4 (C-7), 28.3 (C-6), 32.4 (C-2), 46.9 (C-8), 60.0 (C-5a), 61.0 
(CH2), 62.1 (C-10a), 63.9 (C-3), 118.2 (C-50), 119.7 (C-30), 127.3 (C-40), 
133.1 (C-60), 149.1(C-20), 163.9, 167.1, 168.1 (C=O). Anal. Calculated for 
C18H20BrN3O4S: C, 47.58; H, 4.44; Br, 17.59; N, 9.25; S, 7.06. Found: C, 




FC in dichloromethane/acetone 95/5. Oil (20%); 
25
D -176.2 (c 0.12 in 
CHCl3); 
1
HNMR (400 MHz, CDCl3)  1.32 (3H, t, CH2CH3), 1.58–1.63 (1H, 
m, H-7a), 1.93–1.95 (1H, m, H-7b), 2.37–2.41 (2H, m, H-6), 3.05–3.10 (2H, 
m, H-1), 3.28–3.35 (1H, m, H-8a), 3.77– 3.84 (1H, m, H-8b), 4.21–4.25 (1H, 
m, H-5a), 4.30–4.32 (2-H, q, CH2CH3), 4.86 (1H, d, J = 5.8 Hz, H-10a), 6.59 
(1H, d, J = 8.8 Hz, H-30), 6.92 (1H, s, H-60), 7.20 (1H, d, H-40); 13C NMR 
(100 MHz, CDCl3)  14.3 (CH3), 22.4 (C-7), 28.4 (C-6), 32.7 (C-2), 45.3 (C-
8), 61.9 (C-5a), 62.3 (CH2), 62.5 (C-10a), 68.3(C-3), 109.2 (C-50), 121.1 (C-
30), 123.6 (C-10), 128.8 (C-40), 133.2 (C-60), 145.2 (C-20), 162.8, 164.9, 
168.3 (C=O). Anal. Calculated for C18H20BrN3O4S: C, 47.58; H, 4.44; Br, 
17.59; N, 9.25; S, 7.06. Found: C, 47.51; H, 4.38; Br, 17.80; N, 9.07; S, 7.19. 
 
 
8.7. General procedure for the synthesis of spiro-indol-2-one[3,30]-
hexahydro-5,10H-pyrrolo[1,2-a][1,3]thiazolo[3,4-d]pyrazine-5,10-dione 
derivatives (29a,b–32a,b) 
To a solution of the corresponding spirooxoindolethiazolidine carboxylic acids 
(33a,b–36a,b, 3 mmol) in 29/1 dichloromethane/DMF (300 mL), L-Pro-OMe 
(1.1 equiv), DIC (1.2 equiv), HOBt (1.2 equiv), and DIPEA (2.4 equiv) were 




Afterward, the reaction mixture was diluted with dichloromethane (20 mL), 
and the resulting solution was washed successively with 10% NaHCO3 (2 x 50 
mL) and water (2 x 50 mL), dried over Na2SO4, and evaporated to dryness. 
Flash chromatography of the residues, using different eluent systems, yielded, 
in each case, the correspondent 40- (carbonyl-prolyl-OMe) spirooxindole 
thiazolidine derivatives as diasteroisomeric mixture (37a,b–40a,b) which were 
not separated in this step. 
A solution of derivatives 37a,b or 37a,b or 39a,b or 40a,b (1 mmol) was 
treated with 1/4: 2 N HClaq/MeOH solution (10 mL) and stirred at room 
temperature. After 2 h, the mixtures were concentrated and dissolved in DCM. 
10% NaHCO3 solution was added until pH 7 and the resulting mixtures were 
washed with water (3 x 25 mL), dried over Na2SO4, evaporated to dryness, 
and purified and separated by flash column chromatography using different 




FC in ethyl acetate. White solid (31%); mp 175–176  °C; 25D_76.3 (c 0.13 in 
CHCl3); 1H NMR (400 MHz, CDCl3)  1.90–2.02 (3H, m, H-60 , H-7’a), 
2.17–2.25 (1H, m, H-7’b), 3.51–3.58 (3H, m, H-80 , H-1’a), 3.78–3.83 
(1H, m, H-1’b), 4.22 (1H, t, H-5’a); 5.01 (1H, dd, J = 6.0 and 10.0 Hz, H-
10‘ a), 6.79 (1H, d, J = 8.0 Hz, H-7), 7.01 (1H, t, H-5), 7.18 (1H, d, J = 8.0 Hz, 
H-4), 7.24 (1H, t, H-6), 8.03 (1H, s, NH); 13C NMR (100 MHz, CDCl3)  
23.6 (C-60), 27.4 (C-70), 33.9 (C-10), 45.8 (C-80), 60.1 (C-50a), 66.3 (C-
100a), 70.2 (C-3), 114.2 (C-7), 123.8 (C-4), 125.1 (C-5), 127.2 (C-3a), 131.5 
(C-6),140.7(C-7a), 163.8, 164.6, 175.2 (C=O). Anal. Calculated for 
C16H15N3O3S: C, 58.34; H, 4.59; N, 12.76; S, 9.74. Found: C, 58.21; H, 4.48; 






FC in ethyl acetate. White solid (37%); mp 190–191 °C; 25 D  - 104.1 (c 0.11 
in CHCl3); 
1
H NMR (400 MHz, CDCl3) 1.92–2.06 (3H, m, H-60 , H-7’a), 
2.23–2.30 (1H, m, H-7’b), 3.58–3.69 (3H, m, H-80 , H-1’a); 3.81 (1H, t, H-
1’b); 4.27 (1H, t, H-5’a); 5.04 (1H, dd, J = 6.0 and 10.0 Hz, H-10‘ a), 6.81 
(1H, d, J = 8.0 Hz, H-7), 7.02 (1H, t, H-5), 7.21 (1H, d, J = 8.0 Hz, H-4), 7.26 
(1H, t, H-6), 7.83 (1H, s, NH); 13C NMR (100 MHz, CDCl3)  23.2 (C-60), 
28.0 (C-70), 33.5 (C-10), 45.6 (C-80), 60.8 (C-50a), 66.1 (C-100a), 70.4 (C-3), 
114.5 (C-7), 123.3 (C-4), 124.2 (C-5), 126.8 (C-3a), 130.6 (C-6), 140.9 (C-7a), 
163.7, 164.5, 175.9 (C=O). Anal. Calculated for C16H15N3O3S: C, 58.34; H, 
4.59; N, 12.76; S, 9.74. Found: C, 58.20; H, 4.50; N, 12.59; S, 9.91. 
 
(3R,5’aS,10’aR) 5-Methyl spiro[[indol-2-one[3,30]-hexahydro-5,10H-
pyrrolo[1,2-a][1,3]thiazolo[3,4-d] pyrazine]]-5,10-dione (30a) 
FC in ethyl acetate. White solid (29%); mp 181–183 _C; 25D - 40.3 (c 0.12 in 
CHCl3); 1H NMR (400 MHz, CDCl3) d 1.93–1.97 (1H, m, H-6’a), 2.05–
2.11 (2H, m, H-6’b, H-7’a), 2.22–2.26 (1H, m, H-7’b), 2.30 (3H, s, CH3), 
3.51–3.69 (3H, m, H-80 , H-1’a), 3.83 (1H, t, H-1’b), 4.28 (1H, t, H-5’a), 
5.02 (1H, dd, J = 6.0 and 10.0 Hz, H-10‘ a), 6.74 (1H, d, J = 8.0 Hz, H-7), 7.38 
(1H, d, H-6), 7.41 (1H, s, H-4), 7.92 (1H, s, NH); 13C NMR (100 MHz, 
CDCl3) d 23.2 (C-60), 24.6 (CH3), 27.9 (C-70), 33.5 (C-10), 45.6 (C-80), 60.4 
(C-50a), 66.1 (C-100a), 69.9 (C-3), 112.1 (C-7), 124.5 (C-3a), 127.5 (C-4), 
133.0 (C-6), 134.7 (C-5), 138.2 (C-7a), 163.6, 164.9, 175.4 (C=O). Anal. 
Calculated for C17H17N3O3S: C, 59.46; H, 4.99; N, 12.24; S, 9.34. Found: 






pyrrolo[1,2-a][1,3]thiazolo[3,4-d] pyrazine]]-5,10-dione (30b) 
FC in ethyl acetate. White solid (35%); mp 190–191 °C; 25D - 130.8 (c 0.2 in 
CHCl3); 1H NMR (400 MHz, CDCl3)  1.95–2.03(3H, m, H-6’a, H-70), 
2.24–2.30 (1H, m, H-6’b), 2.33 (3H, s, CH3), 3.57–3.64 (3H, m, H-80 ,      
H-1 ’a); 3.82 (1H, t, H-1’b); 4.35 (1H, t, H-5’a); 5.04 (1H, dd, J = 5.6 and 
10.8 Hz, H-100a), 6.74 (1H, d, J = 8.0 Hz, H-7), 7.39 (1H, d, J = 8.0 Hz, H-6), 
7.42 (1H, s, H-4), 8.59 (1H, s, NH); 13C NMR (100 MHz, CDCl3) 23.5 (C-
60), 24.8 (CH3), 28.0 (C-70), 32.5 (C-10), 45.5 (C-80), 61.0 (C-5‘ a), 65.8 (C- 
10‘ a), 71.1 (C-3), 112.3 (C-7), 122.7 (C-3a), 125.8 (C-4), 132.3 (C- 5), 132.9 
(C-6), 136.2 (C-7a), 164.2, 166.5, 174.3 (C=O). Anal. Calculated for 
C17H17N3O3S: C, 59.46; H, 4.99; N, 12.24; S, 9.34. Found C, 59.51; H, 5.08; 
N, 12.17; S, 9.52. 
 
(3R,50aS,100aR) 5-Bromo Spiro[[indol-2-one[3,30]-hexahydro- 
5,10H-pyrrolo[1,2-a][1,3] thiazolo[3,4-d] pyrazine]]-5,10-dione (31a) 
FC in ethyl acetate. White solid (28%); mp 178–179 ° C; 25D -68.0 (c 0.12 in 
CHCl3); 1H NMR (400 MHz, CDCl3)  1.89–1.96 (1H, m, H-6’a), 2.04–
2.09 (2H, m, H-6’b, H-7’a), 2.19–2.23 (1H, m, H-7’b), 3.49–3.65 (3H, m, 
H-80 , H-1’a), 3.82 (1H, t, H-1’b); 4.26 (1H, t, H-5’a), 5.00 (1H, dd, J = 
6.0 and 10.0 Hz, H-100a), 6.73 (1H, d, J = 8.0 Hz, H-7), 7.38 (1H, d, H-6), 
7.41 (1H, s, H-4) 7.75 (1H, s, NH); 1H NMR (400 MHz, CD3OD) d 1.93–2.03 
(3H, m, H-6’a, H-70), 2.16–2.19 (1H, m, H-6’b), 3.54–3.64 (2H, m, H-80), 
3.65–3.68 (1H, m, H-1’a), 3.65 (1H, t, J 10.0 Hz, H-1’b), 4.43 (1H, m,     
H-5’a), 5.27 (1H, dd, J = 6.4 and 9.6 Hz, H-10‘ a), 6.81 (1H, d, J = 8.0 Hz, 
H-7), 7.42 (1H, d, H-6), 7.55 (1H, s, H-4); 13C NMR (100 MHz, CDCl3)  




71.1 (C-3), 107.8 (C-5), 112.1 (C-7), 123.4 (C-6), 128.8 (C-3a), 130.7 (C-4), 
138.9 (C-7a), 167.1, 169.2, 174.8 (C=O). Anal. Calculated for 
C16H14BrN3O3S: C, 47.07; H, 3.46; Br, 13.57; N, 10.29; S, 7.85. Found C, 
46.91; H, 3.48; Br, 13.71; N, 10.40; S, 7.97. 
 
(3S,5’aS,10’aR) 5-Bromo spiro[[indol-2-one[3,30]-hexahydro-5,10H-
pyrrolo[1,2-a][1,3]thiazolo[3,4-d] pyrazine]]-5,10-dione (31b) 
FC in ethyl acetate. White solid (33%), mp 187–189 °C; 25D -128.6 (c 0.14 in 
CHCl3); 
1
H NMR (400 MHz, CDCl3)  1.94–2.05 (3H, m, H-6’a, H-70), 
2.25–2.30 (1H, m, H-6’b), 3.60–3.67 (3H, m, H-80 , H-1’a), 3.82 (1H, t, H-
1’b), 4.32 (1H, t, H-5’a), 5.06 (1H, dd, J = 5.6 and 10.8 Hz, H-10‘ a), 6.81 
(1H, d, J = 8.0 Hz, H-7), 7.39 (1H, d, H-6), 7.42 (1H, s, H-4), 8.33 (s, NH); 1H 
NMR (400 MHz, CD3OD) d 1.88–2.02 (3H, m, H-6a‘ , H-7‘), 2.20–2.21 (1H, 
m, H-6’b), 3.54– 3.64 (2H, m, H-8‘), 3.65–3.68 (1H, m, H-1’a), 3.84 (1H, 
t, J = 10.4 Hz, H-1’b), 4.43 (1H, m, H-5’a); 5.14 (1H, dd, J = 6.8 and 9.6 
Hz, H-10‘a), 6.81 (1H, d, J = 8.0 Hz, H-7), 7.38 (1H, d, H-6); 7.42 (1H,s, H-
4); 13C NMR (100 MHz, CDCl3) d 23.7 (C-60), 28.2 (C-70), 32.4 (C-10), 
45.8 (C-80), 61.4 (C-50a), 65.9 (C-100a), 70.8 (C-3), 109.9 (C-5), 111.6 (C-7), 
130.4 (C-6), 136.5 (C-4), 139.8 (C-7a), 164.6, 166.0, 174.6 (C=O). Anal. 
Calculated for C16H14BrN3O3S: C, 47.07; H, 3.46; Br, 13.57; N, 10.29; S, 7.85. 
Found C, 46.96; H, 3.39; Br, 13.68; N, 10.42; S, 7.96. 
 
(3R and 3S,50aS,100aR) 1-Methyl spiro[[indol-2-one[3,30]-hexahydro-
5,10H-pyrrolo[1,2-a][1,3]thiazolo[3,4-d]pyrazine]]-5,10-dione (32a,b) 
FC in ethyl acetate. White solid (72%) 1HNMR (400 MHz, CDCl3)  1.83–
2.04 (3H, m, H-60 , H-7’a), 2.11–2.23 (1H, m, H-7’b), 3.21 (3H, s, CH3); 
3.42–3.61 (3H, m, H-80 , H-1’a), 3.78 (1H, t, H-1’b), 4.19 (1H, m,           




6.81 (1H, d, J= 8.0 Hz, H-7), 7.02 (1H, t, H-6), 7.22 (1H, d, J = 8.0 Hz, H-4), 
7.33 (1H, t, H-5). 13C NMR (100 MHz, CDCl3)  23.6, 24.9 (C-6‘), 26.5(C-
7‘), 29.1 and 29.8 (CH3), 39.0 and 42.1 (C-1‘), 46.9 and 52.9 (C-8‘), 59.1     
(C-5‘ a), 62.9 and 66.7 (C-10‘ a), 73.2 (C-3), 108.7, 109.0 (C-7), 123.5 (C-4), 
124.3 (C-5), 129.2 and 130.7 (C-6), 130.1 (C-5), 142.1 (C-7a), 168.1, 169.2, 
172.4, 176.7 (C=O). Anal. Calculated for C17H17N3O3S: C, 59.46; H, 4.99; N, 
12.24; S, 9.34. Found: C, 59.63; H, 4.89; N, 12.59; S, 9.29. 
 
 
8.8. General Procedure for the Synthesis of the (3R,7aR)-6-(Alkyl or 
benzylsubstituted)-spiro[imidazo[1,5-c]thiazole-3,30-indoline]-
20,5,7(6H,7aH)-trione Derivatives (42a-e/45a-e). 
Triphosgene (0.3 mmol) and TEA (0.9 mmol) were added to a solution of 
(20R,4‘R)- and (20S,4‘R)-ethyl 2-oxospiro[indoline-3,20-thiazolidine]-4‘-
carboxylate derivatives (5-8, 200 mg, 0.7 mmol) in dry THF (15 mL). After 
the mixture was stirred at room temperature for 10 min, a solution in dry THF 
of corresponding amines (benzylamine, 4-methylbenzylamine, 4-
chlorobenzylamine, 3,4,5-trimethoxybenzylamine, or 4,4 dimethyl 
cyclohexyilamine, a-e) (0.75 mmol) was added. The reaction mixture was then 
stirred at room temperature for 3 h. Solvent was evaporated, and the residue 
was dissolved in dichloromethane. The organic solution was washed with 
water (3 x 100 mL), dried over Na2SO4, and evaporated in vacuo. The residues 
were dissolved in MeOH and TEA until pH 8.0 was obtained, and the 
mixture was heated to reflux temperature for 2 h. The mixture was then cooled 
to ambient temperature, and solvent was removed in vacuo. The residue was 
dissolved in dichloromethane and washed with water (3 x 100 mL). Flash 
chromatography on silica gel, using ethyl acetate/n-hexane in 3/2 ratio as 
eluent, yielded the correspondent final derivatives. The achieved compounds 





2’,5,7(6H,7aH)-trione (42a).  




 -6.9° (c 0.11, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 3.35 (dd, 1H, J=5.6 and 11.6Hz, Ha-1); 3.72 (t, 1H, Hb-1); 
4.56 (d, 1H, J=14.8 Hz, CH2); 4.71 (d, 1H, CH2); 5.00 (dd, 1H, J=5.6 and 11.2 
Hz, H-7a); 6.83 (d, 1H, J=7.6Hz, H-7 ‗ ); 7.07 (t, 1H, H-6‘); 7.26-7.34 (m, 6H, 
H-5‘ and aryl); 7.39 (d, 1H, H-4
‘
); 7.81 (s, 1H, NH). 
13
C NMR (100 MHz, 
CDCl3) δ 32.4 (C-1), 43.0 (CH2), 68.9 (C-7a), 70.1 (C-3), 110.3, 123.4, 125.3, 
125.8, 129.1, 130.2, 131.5, 133.4, 135.4, 138.2 (aryl), 156.3, 169.9, 176.0 
(C=O). ESIMS m/z calculated for C19H15N3O3S, 365.08; found, 365.13. 
 
(3R,7aR)-6-(4-Methylbenzyl)-1H-spiro[imidazo[1,5-c]thiazole-3,3’-
indoline]-2’,5,7(6H,7aH)-trione (42b).  
1.1.1. Yield 48%, mp 212-213 °C, ]25D
 
 -7.1° (c 0.1, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 2.29 (s, 3H, CH3); 3.33 (dd, 1H, J = 5.6 and 11.2 Hz, Ha-1); 
3.71 (t, 1H, Hb-1); 4.51 (d, 1H, J = 14.4 Hz, CH2); 4.67 (d, 1H,CH2); 4.97 (dd, 
1H, J=5.6 and 10.8 Hz, H-7a); 6.81 (d, 1H, J=7.6 Hz, H-7‘); 7.04-7.11 (m, 6H, 
H-6‘ and aryl); 7.28 (t, 1H, H-5‘); 7.37 (d, 1H, J = 7.6 Hz, H-4‘); 8.06 (s, 1H, 
NH). 
13
C NMR (100 MHz, CDCl3) δ 21.2 (CH3), 32.5 (C-1), 43.1 (CH2), 68.9 
(C-7a), 70.2 (C-3), 110.9, 123.6, 125.3, 125.9, 128.1, 128.4, 128.9, 131.7, 
133.4, 135.2, 138.0 (aryl), 156.4, 169.6, 176.2 (C=O). ESIMS m/z calculated 
for C20H17N3O3S, 379.10; found, 379.18. 
 
(3R,7aR)-6-(4-Chlorobenzyl)-1H-spiro[imidazo[1,5-c]thiazole-3,3’-





8.8° (c 0.12, MeOH). 
1
H NMR (400 MHz, CDCl3) δ 3.35 (dd, 1H, J=5.6 and 
11.2 Hz, Ha-1); 3.71 (t, 1H, Hb-1); 4.53 (d, 1H, J=15.2 Hz, CH2); 4.67 (d, 1H, 
CH2); 5.00 (dd, 1H, J = 5.6 and 10.8 Hz, H-7a); 6.78 (d, 1H, J = 8.0 Hz, H-




8.43 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 32.4 (C-1), 42.5 (CH2), 68.9 
(C-7a), 70.1 (C-3), 111.2, 123.7, 125.3, 125.4, 129.2, 130.1, 131.2, 133.8, 
134.2, 140.8 (aryl), 156.4, 169.9, 176.1 (C=O). ESIMS m/z calculated for 
C19H14ClN3O3S, 399.04; found, 399.13. 
 
(3R,7aR)-6-(3,4,5-Trimethoxybenzyl)-1H-spiro[imidazo[1,5-c]-thiazole-
3,3’-indoline]-2’,5,7(6H,7aH)-trione (42d).  




  -8.2° (c 0.12, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 3.34 (dd, 1H, J0 =5.6 and 11.6 Hz, Ha-1); 3.66 (t, 1H, Hb-1); 
3.72 (s, 3H, OCH3,); 3.81 (s, 6H, OCH3); 4.46 (d, 1H, J=14.4 Hz, CH2); 4.64 
(d, 1H, CH2); 5.00 (dd, 1H,J=5.2 and 10.6 Hz, H-7a); 6.56 (s, 2H, aryl); 6.83 
(d, 1H, J =7.2 Hz, H-70); 7.09 (t, 1H, H-6‘); 7.25 (t, 1H, H-5‘); 7.38 (d, 1H, H-
4‘); 8.22 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 32.5 (C-1), 43.3 (CH2), 
56.4 (OCH3), 68.9 (C-7a), 70.6 (C-3), 105.4, 110.8, 125.4, 126.0, 130.9, 131.2, 
133.5, 137.2, 138.4, 154.9 (aryl), 156.3, 169.4, 175.7 (C=O). ESIMS m/z 
calculated for C22H21N3O6S, 455.12; found, 455.25. 
 
(3R,7aR)-6-(4,4-Dimethylcyclohexyl)-1H-spiro[imidazo[1,5-c]-thiazole-
3,3’-indoline]-2’,5,7(6H,7aH)-trione (42e).  




  -8.1° (c 0.1, MeOH). 
1
H NMR (400 MHz, 
CDCl3) δ 0.89 (s, 3H, CH3); 0.93 (s, 3H, CH3); 1.19-1.25 (m, 2H, CH2); 1.41-
1.49 (m, 4H, CH2); 2.21-2.33 (m, 2H, CH2); 3.32 (dd, 1H, J=5.2 and 10.8 Hz, 
Ha-1); 3.71 (t, 1H, Hb-1); 3.78-3.82 (m, 1H, CH); 4.93 (dd, 1H, J = 5.6 and 
10.8 Hz, H-7a); 6.85 (d, 1H, J = 7.6 Hz, H-7‘); 7.08 (t, 1H, H-6‘); 7.27 (t, 1H, 
H-5‘); 7.41 (d, 1H, H-4‘); 8.06 (s, 1H,NH). 
13
CNMR(100 MHz, CDCl3) δ 24.8 
(CH2); 25.4 (CH2); 26.7 (CH3); 29.9 (CH3); 32.3 (C-1), 38.7 (CH), 52.8 (C), 
68.7 (C-7a), 70.6 (C-3), 109.6, 123.6, 125.0, 125.3, 131.1, 143.6 (aryl), 156.6, 






indoline]-2’,5,7(6H,7aH)-trione (43a).  




  -12.4° (c 0.11, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 2.30 (s, 3H, CH3); 3.33 (dd, 1H, J=5.2 and 11.2 Hz, Ha-1); 
3.73 (t, 1H, Hb-1); 4.56 (d, 1H, J=14.8 Hz, CH2); 4.71 (d, 1H, CH2); 5.00 (dd, 
1H, J = 5.6 and 10.8 Hz, H-7a); 6.70 (d, 1H, J=8.0 Hz, H-7‘); 7.05 (d, 1H, H-
6‘); 7.23 (s, 1H, H-4‘); 7.26-7.36 (m, 5H, aryl); 8.11 (s, 1H,NH). 
13
CNMR(100 
MHz, CDCl3) δ 21.2 (CH3); 32.4 (C-1), 43.2 (CH2), 68.9 (C-7a), 70.3 (C-3), 
110.9, 125.3, 126.0, 128.3, 128.7, 128.9, 131.6, 133.4, 135.4, 138.2 (aryl), 




3,3’-indoline]-2’,5,7(6H,7aH)-trione (43b).  




  -12.5° (c 0.11, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 2.30 (s, 6H, CH3); 3.31 (dd, 1H, J=5.6 and 11.6 Hz, Ha-1); 
3.71 (t, 1H, Hb-1); 4.51 (d, 1H, J= 14.8 Hz, CH2); 4.67 (d, 1H, CH2); 4.97 (dd, 
1H, J=5.2 and 10.8 Hz, H-7a); 6.72 (d, 1H, J = 8.0 Hz, H-7‘); 7.07-7.26 (m, 
6H,H-4‘, H-60, and aryl); 7.72 (s, 1H, NH). 
13
CNMR (100 MHz, CDCl3) δ 
21.2 (CH3); 21.3 (CH3); 32.5 (C-1), 42.9 (CH2), 68.9 (C-7a), 70.2 (C-3), 
110.7, 125.3, 126.1, 128.7, 129.5, 131.5, 133.6, 135.8, 138.0 (aryl), 156.5, 




3,3’-indoline]-2’,5,7(6H,7aH)-trione (43c).  




 -14.5° (c 0.13, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 2.29 (s, 3H, CH3); 3.30 (dd, 1H, J = 5.6 and 11.6 Hz, Ha-1); 




(dd, 1H, J = 4.8 and 10.4 Hz, H-7a); 6.72 (d, 1H, J=8.0 Hz, H-7‘); 7.05 (d, 1H, 
H-6‘); 7.20-7.26 (m, 5H, H-4‘ and aryl); 8.54 (s, 1H, NH). 
13
C NMR (100 
MHz, CDCl3) δ 21.2 (CH3); 32.3 (C-1), 42.4 (CH2), 68.9 (C-7a), 70.3 (C-3), 
110.9, 125.3, 126.0, 129.1, 130.1, 131.6, 133.3, 133.9, 134.2, 138.4 (aryl), 









  -13.9° (c 0.11, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 2.31 (s, 3H, CH3); 3.28 (dd, 1H, J = 5.6 and 11.6 Hz, Ha-1); 
3.64 (t, 1H, Hb-1); 3.73 (s 3H, OCH3,); 3.76 (s 6H, OCH3,); 4.39 (d, 1H, 
J=14.8Hz, CH2); 4.59 (d, 1H, CH2); 4.94 (dd, 1H, J = 5.6 and 10.8 Hz, H-7a); 
6.50 (s, 2H, aryl); 6.45 (d, 1H, J=8.0Hz,H-7‘); 6.99 (d, 1H, H-6‘); 7.16 (s, 1H, 
H-4‘); 8.04 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 21.2 (CH3); 32.5 (C-
1), 43.4 (CH2), 56.4 (OCH3); 68.9 (C-7a), 70.6 (C-3), 105.5, 110.9, 125.3, 
126.0, 131.1, 131.6, 133.4, 137.9, 138.2, 153.6 (aryl), 156.4, 169.9, 175.8 








  -13.6° (c 0.12, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 0.89 (s, 3H, CH3); 0.93 (s, 3H, CH3); 1.18-1.30 (m, 2H, CH2); 
1.41-1.48 (m, 4H, CH2); 2.21-2.29 (m, 2H, CH2); 2.31 (s, 3H, CH3); 3.32 (dd, 
1H, J = 5.2 and 11.2 Hz, Ha-1); 3.71 (t, 1H, Hb-1); 3.73-3.82 (m, 1H, CH); 
4.91 (dd, 1H, J=5.6 and 10.8 Hz, H-7a); 6.75 (d, 1H, J= 8.0 Hz, H-7‘); 7.08 (d, 
1H, H-6‘); 7.24 (s, 1H, H-4‘); 7.90 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) 
δ 22.4 (CH3); 24.1 (CH2); 24.9 (CH2); 25.0 (CH3); 29.7 (CH3), 32.5 (C-1), 




(aryl), 156.6, 170.5, 174.6 (C=O). ESIMS m/z calculated for C21H25N3O3S, 
399.16; found, 399.21. 
 
(3R,7aR)-6-(Benzyl)-5’-bromo-1H-spiro[imidazo[1,5-c]thiazole-3,3’-
indoline]-2’,5,7(6H,7aH)-trione (44a).  




  -11.8° (c 0.1, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 3.35 (dd, 1H, J=5.3 and 11.3 Hz, Ha-1); 3.72 (t, 1H, Hb-1); 
4.56 (d, 1H, J=14.8 Hz, CH2); 4.71 (d, 1H, CH2); 5.00 (dd, 1H, J = 5.6 and 
11.1 Hz, H-7a); 6.77 (d, 1H, J = 7.2 Hz, H-7‘); 7.26-7.32 (m, 5H, aryl); 7.43 
(d, 1H, H-6‘); 7.54 (s, 1H, H-4‘); 8.01 (s, 1H, NH). 
13
C NMR (100 MHz, 
CDCl3) δ 32.3 (C-1), 43.9 (CH2), 69.1 (C-7a), 72.2 (C-3), 113.3, 123.4, 125.8, 
128.3, 130.2, 131.5, 133.6, 136.2, 139.1 (aryl), 156.1, 169.8, 175.8 (C=O). 








 -10.3° (c 0.1, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 2.29 (s, 3H, CH3); 3.33 (dd, 1H, J=5.3 and 11.0 Hz, Ha-1); 
3.71 (t, 1H, Hb-1); 4.51 (d, 1H, J= 14.5 Hz, CH2); 4.67 (d, 1H, CH2); 4.97 (dd, 
1H, J = 5.6 and 
10.8 Hz,H-7a); 6.79 (d, 1H, J=7.5Hz, H-7‘); 7.04-7.11 (m, 4H, aryl); 7.41 (d, 
1H, H-6‘); 7.51 (s, 1H, H-4‘); 8.00 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) 
δ 21.5 (CH3), 32.4 (C-1), 43.0 (CH2), 68.9 (C-7a), 71.9 (C-3), 115.2, 125.3, 
128.1, 129.4, 129.9, 132.9, 133.7, 136.2, 139.0 (aryl), 156.2, 169.6, 176.2 








3,3’-indoline]-2’,5,7(6H,7aH)-trione (44c).  




 -11.9° (c 0.11, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 3.30 (dd, 1H, J = 5.5 and 11.1 Hz, Ha-1); 3.69 (t, 1H, Hb-1); 
4.50 (d, 1H, J = 15.2 Hz, CH2); 4.63 (d, 1H,CH2); 4.98 (dd, 1H, J=4.8 and 
10.4 Hz, H-7a); 6.75 (d, 1H, J=7.1 Hz, H-7‘); 7.20-7.26 (m, 4H, aryl); 7.43 (d, 
1H, H-6‘); 7.55 (s, 1H, H-4‘); 8.11 (s, 1H,NH). 
13
C NMR(100 MHz, CDCl3) δ 
32.3 (C-1), 42.4 (CH2), 69.0 (C-7a), 72.0 (C-3), 115.2, 125.3, 126.0, 129.1, 
130.1, 132.1, 133.9, 134.2, 140.7 (aryl), 156.4, 168.9, 176.0 (C=O). ESIMS 








  -12.3° (c 0.13, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 3.38 (dd, 1H, J = 5.6 and 11.6 Hz, Ha-1); 3.72 (t, 1H, Hb-1); 
3.79 (s 3H, OCH3,); 3.82 (s, 6H, OCH3,); 4.47 (d, 1H, J = 14.4 Hz, CH2); 4.64 
(d, 1H, CH2); 5.02 (dd,1H,J=5.2 and 10.4 Hz,H-7a); 6.51 (s,2H, aryl); 6.77 (d, 
1H, J = 7.2 Hz, H-7‘ ); 7.45 (d, 1H, H-6‘); 7.56 (s, 1H, H-4‘); 8.02 (s, 1H, 
NH). 
13
C NMR (100 MHz, CDCl3) δ 32.5 (C-1), 43.3 (CH2), 56.2 (OCH3); 
69.1 (C-7a), 71.9 (C-3), 105.3, 115.9, 125.6, 131.1, 131.6, 133.4, 137.9, 139.1, 
153.6 (aryl), 156.4, 169.9, 175.8 (C=O). ESIMS m/z calculated for 








  -13.1° (c 0.12, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 0.88 (s, 3H, CH3); 0.92 (s, 3H, CH3); 1.18-1.26 (m, 2H, CH2); 
1.41-1.49 (m, 4H, CH2); 2.23-2.33 (m, 2H, CH2); 3.32 (dd, 1H, J = 5.3 and 




J=5.3 and 10.8Hz,H-7a); 6.73 (d, 1H, J=7.01Hz, H-7‘); 7.46 (d, 1H, H-6‘); 
7.56 (s, 1H, H-4‘); 8.00 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 24.9 
(CH2), 25.2 (CH2), 27.9 (CH3), 29.3 (CH3), 32.4 (C-1), 38.9 (CH), 52.7 (C), 
69.0 (C-7a), 71.6 (C-3), 116.1, 125.3, 131.1, 133.9, 140.1 (aryl), 156.6, 170.5, 




indoline]-2’,5,7(6H,7aH)-trione (45a).  




 -16.2° (c 0.11, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 3.27 (s, 3H, CH3); 3.35 (dd, 1H, J=5.2 and 11.2 Hz, Ha-1); 
3.76 (t, 1H, Hb-1); 4.54 (d, 1H, J=14.4 Hz, CH2); 4.71 (d, 1H, CH2); 4.98 (dd, 
1H, J=5.6 and 11.2 Hz, H-7a); 6.86 (d, 1H, J=8.0 Hz, H-7‘); 7.10 (t, 1H, H-
6‘); 7.26-7.38 (m, 6H, H-5‘ and aryl); 7.41 (d, 1H, H-4‘). 
13
C NMR (100 MHz, 
CDCl3) δ 26.8 (CH3), 32.4 (C-1), 42.9 (CH2), 68.7 (C-7a), 70.3 (C-3), 110.0, 
123.6, 125.4, 128.7, 129.9, 131.3, 132.6, 138.1, 143.8 (aryl), 156.2, 169.8, 
174.5 (C=O). ESIMS m/z calculated for C20H17N3O3S, 379.10; found, 379.19. 
 
(3R,7aR)-10-Methyl-6-(4-methylbenzyl)-1H-spiro[imidazo-[1,5-c]thiazole-
3,3’-indoline]-2’,5,7(6H,7aH)-trione (45b).  




  -15.3° (c 0.1, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 2.29 (s, 3H, CH3); 3.28 (s, 3H, CH3); 3.33 (dd, 1H, J=5.2 and 
10.8 Hz, Ha-1); 3.74 (t, 1H, Hb-1); 4.48 (d, 1H, J=14.4 Hz, CH2); 4.67 (d, 1H, 
CH2); 4.96 (dd, 1H, J=5.6 and 11.2 Hz, H-7a); 6.85 (d, 1H, J = 7.6 Hz, H-7‘); 
7.09-7.26 (m, 5H, H-6‘ and aryl); 7.33-7.41 (m, 2H, H-5‘ and H-4‘). 
13
C NMR 
(100 MHz, CDCl3) δ 21.8 (CH3), 26.9 (CH3), 32.5 (C-1), 42.8 (CH2), 68.9 (C-
7a), 70.2 (C-3), 109.2, 123.7, 125.1, 128.8, 129.6, 131.2, 132.5, 138.0, 143.6 
(aryl), 156.2, 169.8, 174.5 (C=O). ESIMS m/z calculated for C21H19N3O3S, 





3,3’-indoline]-2’,5,7(6H,7aH)-trione (45c).  




 -17.1° (c 0.13, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 3.30 (s, 3H, CH3); 3.33 (dd, 1H, J=5.2 and 10.8 Hz, Ha-1); 
3.74 (t, 1H, Hb-1); 4.49 (d, 1H, J= 14.4 Hz, CH2); 4.67 (d, 1H, CH2); 4.96 (dd, 
1H, J=5.6 and 11.2 Hz, H-7a); 6.85 (d, 1H, J = 8.0 Hz, H-7‘); 7.09-7.26 (m, 
5H, H-6‘ and aryl); 7.33-7.41 (m, 2H, H-5‘ and H-4‘); 
13
C NMR (100 MHz, 
CDCl3) δ 26.4 (CH3); 32.7 (C-1), 42.8 (CH2), 68.9 (C-7a), 70.4 (C-3), 110.9, 
125.6, 126.2, 129.3, 130.4, 131.7, 133.5, 133.8, 134.1, 138.2 (aryl), 156.3, 









 -16.1° (c 0.1, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 3.18 (s, 3H, CH3,); 3.33 (dd, 1H, J = 5.6 and 11.6 Hz, Ha-1); 
3.64 (t, 1H, Hb-1); 3.71 (s 3H, OCH3,); 3.79 (s, 6H, OCH3,); 4.48 (d, 1H, J = 
14.4 Hz, CH2); 4.62 (d, 1H, CH2); 5.04 (dd, 1H, J=5.2 and 10.4Hz, H-7a); 6.48 
(s 2H, benzyl); 6.81 (d, 1H, J=7.2 Hz, H-7‘); 7.12 (t, 1H, H-6‘); 7.26 (t, 1H,H-
5‘); 7.35 (d, 1H,H-4‘). 
13
C NMR (100MHz,CDCl3) δ, 26.2 (CH3); 32.6 (C-1), 
43.8 (CH2), 56.7 (OCH3); 68.9 (C-7a), 70.3 (C-3), 105.7, 110.6, 125.3, 126.1, 
129.8, 133.4, 138.2, 153.6 (aryl), 156.5, 169.8, 175.6 (C=O). ESIMS m/z 








 -16.8° (c 0.1, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 0.89 (s, 3H, CH3); 0.94 (s, 3H, CH3); 1.19-1.25 (m, 2H, CH2); 




1H, J = 5.2 and 10.8 Hz, Ha-1); 3.72 (t, 1H, Hb-1); 3.70-3.76 (m, 1H, CH); 
4.90 (dd, 1H, J=5.6 and 11.2 Hz, H-7a); 6.85 (d, 1H, J= 7.6 Hz, H-7‘); 7.11 (t, 
1H, H-6‘); 7.34 (t, 1H, H-5‘); 7.43 (d, 1H, H-4‘). 
13
C NMR (100 MHz, CDCl3) 
δ 24.1 (CH2); 24.9 (CH2); 25.0 (CH3); 26.9 (CH3); 29.7 (CH3); 32.5 (C-1), 
38.6 (CH), 52.5 (C), 68.3 (C-7a), 70.7 (C-3), 109.2, 123.6, 125.3, 131.0, 143.5 
(aryl), 156.5, 170.5, 174.6 (C=O). ESIMS m/z calculated for C21H25N3O3S, 
399.16; found, 399.27. 
 
 
8.9 General Procedure for the Synthesis of the (3R,7aR)-10-Acyl-6-
(benzylsubstituted)-1H-spiro[imidazo[1,5-c]thiazole-3,3’-indoline]-
2’,5,7(6H,7aH)-trione Derivatives (46f-i/47f-i).  
42c or 43d (100 mg, 0.2 mmol) was dissolved in dichloromethane (10 mL), 
and the appropriate acyl chloride (benzoyl chloride, 4-methylbenzoyl chloride, 
4-chlorobenzoyl chloride or butirroyl chloride, f-i) (0.22 mmol) and TEA 
(0.30 mmol) were added. The mixture was stirred at room temperature for 2 h. 
Then the organic solution was washed with 10% NaHCO3 and water, dried 
over Na2SO4, and evaporated to dryness. Flash chromatography was 
performed on silica gel, using as eluent a mixture ethyl acetate/n-hexane, 1/3, 
to obtain the corresponding N-substituted derivatives as white solids. 
 
(3R,7aR)-10-Benzoyl-6-(4-chlorobenzyl)-1H-spiro[imidazo-[1,5-c]thiazole-
3,3’-indoline]-2’,5,7(6H,7aH)-trione (46f).  




 -9.3° (c 0.1, MeOH). 
1
H NMR (400 MHz, 
CDCl3) δ 3.36 (dd, 1H, J=6.0 and 12.0 Hz, Ha-1); 3.60 (t, 1H, Hb-1); 4.45 (d, 
1H, J=14.4 Hz, CH2); 4.63 (d, 1H, CH2); 5.03 (dd, 1H, J = 5.6 and 10.8 Hz, H-
7a); 7.29 (t, 1H, H-6‘); 7.42-7.48 (m, 3H, H-5‘ and aryl); 7.55 (d, 1H, H-4‘); 
7.61 (t, 1H, aryl); 7.77-7.80 (m, 2H, aryl); 7.83 (d, 1H, H-7‘). 
13
C NMR (100 




125.5, 126.0, 128.7, 129.4, 130.1, 130.3, 131.7, 133.3, 137.6, 144.5 (aryl), 
156.2, 167.8, 169.1, 174.3 (C=O). ESIMS m/z calculated for C26H18ClN3O4S, 








  -8.1° (c 0.1, MeOH). 
1
HNMR (400MHz, 
CDCl3) δ 2.40 (s, 3H, CH3); 3.35 (dd, 1H, J= 5.6 and 11.6 Hz, Ha-1); 3.62 (t, 
1H, Hb-1); 4.46 (d, 1H, J = 14.8 Hz, CH2); 4.61 (d, 1H, CH2); 5.02 (dd, 1H, J 
= 5.2 and 10.8 Hz, H-7a); 7.24 (t, 1H, H-6‘); 7.42 (t, 1H, H-5‘); 7.56 (d, 1H, J 
= 8.0 Hz, H-4‘); 7.78 (d, 2H, J = 8.0 Hz, aryl); 7.81 (d, 1H, H-7‘); 7.59 (d, 2H, 
aryl); 
13
C NMR (100 MHz, CDCl3) δ 21.8 (CH3), 32.7 (C-1), 42.5 (CH2), 68.9 
(C-7a), 70.7 (C-3), 115.7, 124.8, 125.2, 125.9, 128.9, 129.2, 129.9, 130.1, 
130.2, 131.6, 133.7, 137.1, 144.6 (aryl), 156.6, 167.8, 169.5, 174.3 (C=O). 








  -7.8° (c 0.12, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 3.34 (dd, 1H, J = 5.6 and 11.6 Hz, Ha-1); 3.59 (t, 1H, Hb-1); 
4.52 (d, 1H, J = 14.8 Hz, CH2); 4.62 (d, 1H, CH2); 5.02 (dd, 1H, J=5.2 and 
10.8Hz, H-7a); 7.31 (t,1H,H-6‘); 7.43 (d, 2H, J=8.0Hz, aryl); 7.48 (t, 1H,H-
5‘); 7.53 (d, 1H, J = 8.0 Hz, H-4‘); 7.78 (d, 2H, aryl); 7.87 (d, 1H, H-7‘); 
13
C 
NMR (100 MHz, CDCl3) δ 32.5 (C-1), 43.6 (CH2), 68.9 (C-7a), 70.9 (C-3), 
115.8, 124.4, 125.3, 126.2, 128.8, 129.2, 130.0, 131.4, 131.7, 137.7, 137.9, 
138.1, 139.0, 141.5 (aryl), 156.8, 167.6, 169.4, 174.1 (C=O). ESIMS m/z 






3,3’-indoline]-2’,5,7(6H,7aH)-trione (46i).  




  -7.3° (c 0.1, MeOH). 
1
H NMR (400 MHz, 
CDCl3) δ 1.04 (t, 3H, CH3); 1.72-1.82 (m, 2H, CH2); 2.96-3.08 (m, 2H, CH2); 
3.37 (dd, 1H, J = 5.6 and 11.6 Hz, Ha-1); 3.67 (t, 1H, Hb-1); 4.52 (d, 1H, 
J=14.4 Hz, CH2); 4.64 (d, 1H, CH2); 5.01 (dd, 1H, J = 5.2 and 10.8 Hz, H-7a); 
7.24 (t, 1H, H-6‘); 7.41 (t, 1H, H-5‘); 7.47 (d, 1H, J =8.0 Hz, H-4‘); 8.25 (d, 
1H, H-7‘); 
13
C NMR (100 MHz, CDCl3) δ 13.9 (CH3), 17.9 (CH2), 32.8 (C-1), 
40.4 (CH2), 42.6 (CH2), 68.9 (C-7a), 71.3 (C-3), 117.5, 124.3, 124.9, 126.1, 
129.2, 130.2, 131.7, 133.7, 134.4, 140.1 (aryl), 157.3, 169.5, 173.7, 175.2 
(C=O). ESIMS m/z calculated for C23H20ClN3O4S, 469.09; found, 469.18. 
 
(3R,7aR)-10-Benzoyl-5’-methyl-6-(3,4,5-trimethoxybenzyl)-1H-
spiro[imidazo[1,5-c]thiazole-3,3’-indoline]-2’,5,7(6H,7aH)-trione (47f).  




  -11.8° (c 0.11, MeOH). 1H NMR (400 
MHz, CDCl3) δ 2.39 (s, 3H, CH3); 3.34 (dd, 1H, J = 6.0 and 12.0 Hz, Ha-1); 
3.59 (t, 1H, Hb-1); 3.66 (s, 3H, OCH3,); 3.78 (s, 6H, OCH3,); 4.43 (d, 1H, J = 
14.4 Hz, CH2); 4.62 (d, 1H, CH2); 5.02 (dd, 1H, J = 5.6 and 10.8 Hz, H-7a); 
6.47 (s, 2H, aryl); 7.23-7.26 (m, 2H, H-6‘ and H-7‘); 7.36 (s, 1H, H-4‘); 7.41-
7.45 (m, 2H, aryl); 7.58 (t, 1H, aryl); 7.80-7.83 (m, 2H, aryl). 
13
C NMR (100 
MHz, CDCl3) δ 21.5 (CH3); 32.4 (C-1), 42.8 (CH2), 56.9 (OCH3), 68.9 (C-7a), 
71.2 (C-3), 105.5, 115.9, 124.6, 125.8, 126.9, 128.7, 129.3, 130.2, 131.8, 
131.3, 132.0, 133.6, 153.5 (aryl), 156.6, 167.2, 169.4, 174.1 (C=O). ESIMS 
m/z calculated for C30H27N3O7S, 573.16; found, 573.21. 
 
(3R,7aR)-5’-Methyl-10-(4-methylbenzoyl)-6-(3,4,5-trimethoxybenzyl)-1H-
spiro[imidazo[1,5-c]thiazole-3,3’-indoline]-2’,5,7-(6H,7aH)-trione (47g).  




 -12.7° (c 0.11, MeOH). 
1
H NMR (400 




11.6 Hz, Ha-1); 3.60 (t, 1H, Hb-1); 3.67 (s 3H, OCH3,); 3.76 (s, 6H, OCH3,); 
4.42 (d, 1H, J=14.8 Hz, CH2); 4.62 (d, 1H, CH2); 5.01 (dd, 1H, J=5.2 and 10.8 
Hz, H-7a); 6.49 (s 2H, aryl); 7.23-7.26 (m, 3H, H-6‘, H-7‘ and aryl); 7.35 (s, 
1H, H-4‘); 7.71-7.77 (m, 3H, aryl). 
13
C NMR (100 MHz, CDCl3) δ: 21.2 
(CH3); 21.8 (CH3), 32.6 (C-1), 42.7 (CH2), 56.5 (OCH3), 68.8 (C-7a), 70.9 (C-
3), 105.4, 115.8, 124.7, 125.5, 128.9, 129.6, 130.4, 131.5, 131.6, 132.9, 133.6, 
137.3, 154.0 (aryl), 156.8, 167.3, 169.1, 174.3 (C=O). ESIMS m/z calculated 
for C31H29N3O7S, 587.17; found, 587.29. 
 
(3R,7aR)-10-(4-Chlorobenzoyl)-5’-methyl-6-(3,4,5-trimethoxybenzyl)- 1H-
spiro[imidazo[1,5-c]thiazole-3,3’-indoline]-2’,5,7- (6H,7aH)-trione (47h).  




 -13.5° (c 0.13, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 2.39 (s, 3H, CH3); 3.32 (dd, 1H, J0 = 5.6 and 11.6 Hz, Ha-1); 
3.61 (t, 1H, Hb-1); 3.69 (s, 3H, OCH3,); 3.77 (s, 6H, OCH3,); 4.43 (d, 1H, 
J=14.8 Hz, CH2); 4.64 (d, 1H, CH2); 5.03 (dd, 1H, J= 5.2 and 10.8 Hz, H-7a); 
6.49 (s, 2H, aryl); 7.26 (d, 1H, J = 8.0 Hz, H-7‘); 7.36 (s, 1H, H-4‘); 7.41-7.44 
(m, 2H, H-6‘, and aryl); 7.72-7.83 (m, 3H, aryl). 
13
C NMR (100 MHz, CDCl3) 
δ 21.4 (CH3); 32.9 (C-1), 43.5 (CH2), 56.3 (OCH3), 68.9 (C-7a), 71.3 (C-3), 
105.1, 115.8, 124.4, 125.6, 128.8, 129.1, 130.8, 131.2, 131.8, 132.2, 136.3, 
137.4, 137.9, 139.7, 153.6 (aryl), 156.7, 167.7, 169.5, 174.4 (C=O). ESIMS 
m/z calculated for C30H26ClN3O7S, 607.12; found, 607.22. 
 
(3R,7aR)-10-Butyryl-5’-methyl-6-(3,4,5-trimethoxybenzyl)-1H-
spiro[imidazo[1,5-c]thiazole-3,3’-indoline]-2’,5,7(6H,7aH)-trione (47i).  




  -14.2° (c 0.15, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 1.00 (t, 3H, CH3); 1.73-1.80 (m, 2H, CH2); 2.32 (s, 3H, CH3); 
3.00 (t, 2H, CH2); 3.37 (dd, 1H, J=5.6 and 11.6 Hz, Ha-1); 3.65 (t, 1H, Hb-1); 
3.81 (s, 3H, OCH3); 3.85 (s, 6H, OCH3,); 4.45 (d, 1H, J = 14.4 Hz, CH2); 4.62 




(d, 1H, J = 8.0 Hz, H-7‘); 7.28 (s, 1H, H-4‘); 8.12 (d, 1H, H-6‘). 
13
C NMR(100 
MHz, CDCl3) δ: 13.5 (CH3), 17.6 (CH2), 21.5 (CH3), 32.7 (C-1), 40.6 (CH2), 
42.9 (CH2), 56.6 (OCH3), 68.9 (C-7a), 71.5 (C-3), 105.6, 117.2, 124.6, 125.8, 
129.1, 130.4, 131.3, 137.7, 139.5, 152.1 (aryl), 157.1, 169.7, 173.2, 175.7 
(C=O). ESIMS m/z calculated for C27H29N3O7S, 539.17; found, 539.28. 
 
 
8.10. Biology.  
modified Eagle‘s medium (DMEM), fetal bovine serum (FBS), trypsin-EDTA 
solution (1_), penicillin and streptomycin, phosphate-buffered saline (PBS) 
were from Cambrex Biosciences. 3-(4,5-Dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT), propidium iodide (PI), Triton X-100, 
sodium citrate, formamide, mouse monoclonal anti-tubulin were purchased 
from Sigma (Milan, Italy). Rabbit polyclonal anti-caspase-3, mouse 
monoclonal anti-PARP-1, mouse monoclonal anti-actin, mouse monoclonal 
anti-p53, and horseradish peroxidase (HRP) conjugated anti-mouse and anti-
rabbit secondary antibodies were purchased from Santa Cruz Biotechnology 
(DBA; Milan, Italy). Rabbit polyclonal anti-cyclin B1 primary antibody were 
from Cell Signaling Technology (Celbio; Milan, Italy). ECL reagent was 
obtained from Amersham Pharmacia Biotech, U.K. 
 
 
8.10.1. Cell Culture. 
Human embryonic kidney HEK 293, human melanoma M14, human 
monocytic leukemia U937, human normal thyroid TAD-2, and human 
papillary thyroid carcinoma TPC1 cell lines cell lines were grown at 37 _C in 
Dulbecco‘s modified Eagle‘s medium containing 10 mM glucose (DMEMHG) 
supplemented with 10% fetal calf serum and 100 units/mL each of penicillin 




placed in fresh medium, cultured in the presence of synthesized compounds 
(from 0.1 to 25 mM), and followed for further analyses. 
 
 
8.10.2. Cell Viability Assay.  
Cell viability for M14, HEK, U937, TPC1n, and TAD-2 cell lines was 




8.10.3. Cytotoxic activity assay 
The human breast adenocarcinoma MCF-7, human ductal breast carcinoma 
T47D, and human epidermoid carcinoma A431 cells were cultured at 37 _C in 
humidified 5%CO2/95% air in Dulbecco‘s Modified Eagle‘s Medium 
(DMEM) containing 10% fetal bovine serum, 2 mM glutamine, 100 U/ml 
penicillin, 100 g/ml streptomycin, 25 mM Hepes and 5 mM sodium pyruvate. 
The cells were plated in 24 culture wells at a density of 2.5 _ 105 cells/ml per 
well or 10 cm diameter culture dishes at a density of 3 _ 106 cells/ml per dish 
and allowed to adhere for 2 h. Thereafter the medium was replaced with fresh 
medium and cells were incubated with isatins (10_7, 10_6, 10_5 M) added to 
the cells for 48 h. Stocks of antitumoral compounds were dissolved in saline or 
saline and 1% DMSO, sterilized by 30 min of UV irradiation and stored at 
20 °C. The cell viability was determined by using 3-(4,5-dimethylthiazol- 
2yl)-2,5-diphenyl-2H-tetrazolium dimethylthiazol-2yl)- 2,5-diphenyl-2H-
tetrazolium bromide (MTT) conversion assay as previously described.26 
Briefly, 100 ml MTT (5 mg/ml in complete DMEM) was added and the cells 
were incubated for an additional 3 h. After this time point the cells were lysed 
and the dark blue crystals solubilized with 500 ml of a solution containing 




4.5. The optical density (OD) of each well was measured with a microplate 
spectrophotometer equipped with a 620 nm filter. The cell viability in 
response to treatment with test compounds was calculated as % dead cells = 
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